Details of the Drug

General Information of Drug (ID: DMNO38U)

Drug Name
Bortezomib
Synonyms
179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
Indication
Disease Entry ICD 11 Status REF
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Lymphoproliferative syndrome N.A. Approved [1]
MALT lymphoma N.A. Approved [1]
Mantle cell lymphoma 2A85.5 Approved [2]
Minimally invasive lung adenocarcinoma N.A. Approved [1]
Multiple myeloma 2A83 Approved [3]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Non-hodgkin lymphoma 2B33.5 Phase 3 [3]
B-cell neoplasm N.A. Investigative [1]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01XG01: Bortezomib
L01XG: Proteasome inhibitors
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 384.2
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 9
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 6
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 57 mcg/L [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance
The total body clearance of drug is 102-112 L/h [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 40 - 193 hours [4]
Metabolism
The drug is metabolized via the CYP3A4, CYP2C19, and CYP1A2 [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0836 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.17% [7]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 10 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 3.3 mg/mL [5]
Chemical Identifiers
Formula
C19H25BN4O4
IUPAC Name
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
Canonical SMILES
B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChIKey
GXJABQQUPOEUTA-RDJZCZTQSA-N
Cross-matching ID
PubChem CID
387447
ChEBI ID
CHEBI:52717
CAS Number
179324-69-7
UNII
69G8BD63PP
DrugBank ID
DB00188
TTD ID
D0SH3I
VARIDT ID
DR01331
INTEDE ID
DR0221
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cationic trypsinogen (PRSS1) TT2WR1T TRY1_HUMAN Inhibitor [8]
Kallikrein-related peptidase (KLK) TT5L2VC NOUNIPROTAC Inhibitor [8]
Proteasome (PS) TTU7ZMG NOUNIPROTAC Modulator [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [14]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
14-3-3 protein epsilon OT3WQXNA 1433E_HUMAN Gene/Protein Processing [15]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [15]
14-3-3 protein zeta/delta OT2TKG9P 1433Z_HUMAN Gene/Protein Processing [15]
2-oxoglutarate dehydrogenase complex component E1 (OGDH) OTHGTQWF ODO1_HUMAN Gene/Protein Processing [15]
26S proteasome non-ATPase regulatory subunit 12 (PSMD12) OTWICA51 PSD12_HUMAN Gene/Protein Processing [15]
26S proteasome non-ATPase regulatory subunit 13 (PSMD13) OTNQ351N PSD13_HUMAN Gene/Protein Processing [15]
26S proteasome non-ATPase regulatory subunit 7 (PSMD7) OT7PZZ4K PSMD7_HUMAN Gene/Protein Processing [15]
26S proteasome regulatory subunit 6B (PSMC4) OTS3XN41 PRS6B_HUMAN Gene/Protein Processing [15]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Gene/Protein Processing [15]
5-hydroxytryptamine receptor 2B (HTR2B) OTM1AD9J 5HT2B_HUMAN Gene/Protein Processing [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 -8.3452 -6.9177 -8.3652 27.2089
ES6 GDSC1; GDSC2 -13.3365 -11.7471 -13.3365 76.8894
ES8 GDSC1; GDSC2 -10.8905 -9.3983 -10.8911 52.6469
NOS-1 [Human HNSCC] GDSC1; GDSC2 -9.5098 -6.6412 -9.6385 39.3348
ES4 GDSC1; GDSC2 -8.755 -6.655 -8.826 31.5759
SK-PN-DW GDSC1; GDSC2 -8.7248 -7.4936 -8.7294 30.9406
ES1 GDSC1; GDSC2 -8.2513 -2.5883 -9.6599 32.7399
CAL-78 GDSC2; CTRP2 -8.0531 -7.1874 -8.0531 34.1728
SK-N-MC CTRP2 -8.0316 -7.3276 -8.0316 34.0287
EW-16 GDSC1; GDSC2 -7.9846 -5.6665 -8.1923 24.5752
CAL-72 GDSC2 -7.884 -6.859 -7.8916 22.5182
ES7 GDSC1; GDSC2 -7.5556 -3.463 -8.562 24.6621
HuO9 GDSC2 -7.3876 -5.3623 -7.6306 18.7965
CHSA8926 GDSC2 -7.3742 -6.1188 -7.427 17.635
EW-7 GDSC2 -7.3078 -5.7259 -7.438 17.3803
SJSA-1 GDSC1; GDSC2; CTRP2 -7.2146 -4.0005 -7.3645 29.0725
A-673 GDSC2; CTRP2 -7.2065 -5.8213 -7.208 28.516
MG-63 GDSC2; CTRP2 -7.1346 -5.4305 -7.1415 28.053
TC-71 GDSC1; GDSC2 -7.1232 -6.265 -7.1405 14.9329
EW-1 GDSC1; GDSC2 -7.089 -5.5965 -7.2342 15.2693
TC71 CTRP2 -6.8936 -5.9987 -6.8937 26.4185
ES5 GDSC1; GDSC2 -6.799 -3.7641 -7.661 16.5576
CADO-ES1 GDSC2 -6.786 -4.7913 -7.1945 13.7393
EW-24 GDSC1; GDSC2 -6.7658 -3.3518 -7.8205 17.3797
CHSA0108 GDSC2 -6.7401 5.0558 -11.9326 33.6765
HOS GDSC2; CTRP2 -6.4863 -5.6485 -6.4864 23.6946
H-EMC-SS GDSC1; GDSC2 -6.4297 -5.4187 -6.5721 8.6555
SK-ES-1 GDSC1; GDSC2; CTRP2 -6.358 -4.1579 -6.4221 22.9989
EW-12 GDSC1; GDSC2 -6.3034 -4.8021 -6.6903 8.831
EW-18 GDSC1; GDSC2 -6.2784 -3.1679 -7.4436 13.3655
SW1353 CTRP2 -6.119 -3.7408 -6.2285 21.613
EW-3 GDSC1; GDSC2 -5.9529 -3.684 -6.8919 8.8484
G-292 clone A141B1 GDSC2; CTRP2 -5.9287 -2.0702 -6.4756 21.8707
HuO-3N1 GDSC2 -5.8787 3.7181 -10.522 27.0892
U-CH2 GDSC2 -5.8738 -2.7975 -7.2629 10.9263
U2OS GDSC2; CTRP2; CTRP1 -5.7441 -3.9939 -5.79 18.8862
EW-22 GDSC1; GDSC2 -5.7273 -3.545 -6.7636 7.3352
EW-11 GDSC1; GDSC2 -5.6904 -2.5242 -7.2426 10.244
NY GDSC2 -5.6791 3.0363 -10.0133 24.6376
MHH-ES-1 GDSC2; CTRP2 -5.6159 -3.6873 -5.6957 18.1461
CHSA0011 GDSC2 -5.5671 -2.2804 -7.262 10.0061
EW-13 GDSC1; GDSC2 -5.5202 -1.2125 -7.7573 12.9118
SaOS-2 GDSC2; CTRP2 -5.017 -3.9309 -5.0317 13.8845
Hs 888.T CTRP2 -3.2249 2.2572 -5.7818 12.458
Hs 822.T CTRP2 0.1308 7.8296 -6.034 7.9949
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 218 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 -8.2712 -7.4954 -8.2712 35.6316
JK1 CTRP2 -6.8142 -3.2453 -7.0892 26.8337
JM1 GDSC1; GDSC2; CTRP2 -8.6512 -8.0481 -8.6512 38.1729
Loucy GDSC1; GDSC2 -11.062 -9.9747 -11.062 54.3713
CESS GDSC1; GDSC2 -10.687 -9.6467 -10.687 50.608
AMO1 GDSC1; GDSC2; CTRP2; CTRP1 -10.4094 -9.6041 -10.4094 49.9313
DND-41 GDSC1; GDSC2 -10.3528 -9.3542 -10.3528 47.2547
H9 GDSC1; GDSC2 -10.2592 -9.2402 -10.2593 46.3159
NK-92MI GDSC1; GDSC2 -10.2464 -9.5629 -10.2464 46.1872
OCI-M1 GDSC1; GDSC2; CTRP2 -10.2049 -9.2663 -10.2049 48.5633
Farage GDSC1; GDSC2 -10.1887 -8.8282 -10.1895 45.6107
Namalwa GDSC1; GDSC2 -10.1714 -8.6952 -10.173 45.44
MY-M12 GDSC1; GDSC2 -10.1534 -9.3917 -10.1534 45.2538
MOLT-4 GDSC1; GDSC2 -10.0843 -9.4817 -10.0843 44.5602
SU-DHL-16 GDSC1; GDSC2 -10.0795 -9.6015 -10.0795 44.5119
P32/ISH GDSC1; GDSC2 -10.067 -9.588 -10.067 44.3871
Karpas-231 GDSC1; GDSC2 -10.0501 -9.5321 -10.0501 44.2171
ML-2 GDSC1; GDSC2 -9.8044 -8.5403 -9.8052 41.7556
BL-41 GDSC1; GDSC2 -9.6524 -8.7509 -9.6524 40.226
WIL2 NS GDSC1; GDSC2 -9.6316 -8.7467 -9.6316 40.0175
VL51 GDSC1; GDSC2 -9.5825 -8.7456 -9.5825 39.5249
KMS-21-BM CTRP2 -9.5098 -8.3584 -9.5098 43.915
OCI-Ly19 GDSC1; GDSC2; CTRP2 -9.4135 -8.7703 -9.4135 43.271
ME1 GDSC1; GDSC2 -9.4064 -8.3958 -9.4066 37.7584
Peer CTRP2 -9.4012 -8.4734 -9.4012 43.1889
A3/Kawakami GDSC1; GDSC2 -9.391 -8.5211 -9.3911 37.6032
JSC-1 GDSC1; GDSC2 -9.3416 -8.0329 -9.344 37.1193
697 GDSC1; GDSC2 -9.2654 -8.2162 -9.2659 36.3451
LC4-1 GDSC1; GDSC2 -9.2131 -7.9701 -9.2151 35.8279
OPM-2 GDSC1; GDSC2; CTRP2 -9.2054 -7.3967 -9.2062 41.8818
KOPN-8 GDSC1; GDSC2 -9.1874 -8.2754 -9.1876 35.5608
EM-2 GDSC1; GDSC2; CTRP2 -9.1563 -7.736 -9.1564 41.5513
Sc-1 GDSC1 -9.1263 -8.5692 -9.1263 43.5303
TK [Human B-cell lymphoma] GDSC1; GDSC2 -9.0628 -8.1611 -9.063 34.3101
HH [Human lymphoma] GDSC1; GDSC2 -9.0518 -7.4622 -9.0648 34.2637
KMOE-2 GDSC1; GDSC2 -9.0352 -7.7967 -9.0379 34.0457
BALL-1 GDSC1; GDSC2 -9.0307 -8.3341 -9.0307 33.9872
DB GDSC1; GDSC2; CTRP2 -9.0172 -8.106 -9.0172 40.6204
KE-37 GDSC1; GDSC2; CTRP2 -9.0151 -8.0794 -9.0151 40.6063
Hs 445 GDSC1; GDSC2 -8.9937 -8.091 -8.9939 33.6173
PF-382 GDSC1; GDSC2; CTRP2 -8.9177 -7.5824 -8.9178 39.9553
BE-13 GDSC1; GDSC2 -8.8885 -7.9647 -8.8889 32.5625
CTV-1 GDSC1; GDSC2 -8.8434 -7.8484 -8.8442 32.1116
JJN-3 GDSC1; GDSC2; CTRP2 -8.7915 -7.9763 -8.7915 39.0181
SU-DHL-6 GDSC1; GDSC2; CTRP2 -8.7827 -7.6945 -8.7827 39.0519
QIMR-WIL GDSC1; GDSC2 -8.7593 -7.121 -8.7818 31.3771
NKM-1 GDSC1; GDSC2 -8.7284 -7.5147 -8.7325 30.9744
Ramos.2G6.4C10 GDSC1; GDSC2 -8.721 -7.2709 -8.7334 30.9415
BL-70 CTRP2; CTRP1 -8.7174 -7.9849 -8.7174 60.0148
NCI-H929 GDSC2; CTRP2 -8.7137 -7.6059 -8.7137 38.5907
ARH-77 GDSC1; GDSC2 -8.7119 -7.7178 -8.713 30.7936
HT GDSC1; GDSC2; CTRP2; CTRP1 -8.7068 -8.0211 -8.7068 59.9684
Pfeiffer CTRP2 -8.6934 -7.1314 -8.6938 38.4564
KG-1 GDSC1; GDSC2 -8.6863 -7.693 -8.6874 30.5369
ATN-1 GDSC1; GDSC2 -8.6663 -7.7107 -8.6672 30.3349
NU-DUL-1 GDSC1; GDSC2; CTRP2; CTRP1 -8.638 -7.0047 -8.6387 38.0866
CCRF-CEM GDSC1; GDSC2 -8.6177 -5.7875 -8.8512 31.0108
BC-3 GDSC1; GDSC2 -8.6079 -7.6948 -8.6086 29.7477
RS4;11 GDSC1; GDSC2; CTRP2 -8.585 -5.8482 -8.6116 37.8144
SUP-B15 GDSC1; GDSC2; CTRP2 -8.5652 -7.4493 -8.5652 37.5975
MOTN-1 CTRP2 -8.5619 -6.6828 -8.5643 37.5833
MOLT-16 GDSC1; GDSC2; CTRP2 -8.5585 -7.6861 -8.5585 37.5527
L-540 GDSC1; GDSC2; CTRP2 -8.5286 -7.8119 -8.5286 37.353
L-1236 GDSC1; GDSC2; CTRP2 -8.4965 -6.9518 -8.4986 35.2221
BCP-1 CTRP2 -8.473 -6.5509 -8.4761 36.9913
SUP-HD1 GDSC1; GDSC2; CTRP2 -8.468 -7.2088 -8.4681 36.9479
KMS-11 GDSC2; CTRP2; CTRP1 -8.4579 -7.3742 -8.4579 36.8801
SEM CTRP2 -8.4524 -7.9228 -8.4524 36.7555
HC-1 GDSC1; GDSC2 -8.4519 -7.1966 -8.4602 28.2207
RPMI-8226 GDSC1; GDSC2; CTRP2; CTRP1 -8.4157 -7.7811 -8.4157 36.598
ALL-SIL GDSC1; GDSC2; CTRP2 -8.3875 -7.45 -8.3875 36.4089
CRO-AP2 GDSC2 -8.3861 -7.2961 -8.39 27.538
RPMI-8402 GDSC1; GDSC2; CTRP2 -8.3719 -7.4609 -8.3719 36.3047
Karpas-1106P GDSC2 -8.3629 -6.9427 -8.3819 27.3819
PL-21 GDSC1; GDSC2 -8.3495 -5.9398 -8.5214 28.0331
A4/Fukuda GDSC1; GDSC2; CTRP2 -8.3135 -7.5998 -8.3135 35.9145
Daudi GDSC1; GDSC2; CTRP2 -8.306 -6.5115 -8.3083 35.8716
Karpas-45 GDSC1; GDSC2 -8.3029 -7.1568 -8.3092 26.7154
EJM GDSC1; GDSC2; CTRP2; CTRP1 -8.2981 -7.2166 -8.2981 35.8115
MOLP-2 CTRP2 -8.2914 -7.5365 -8.2914 35.7667
OCI-AML-3 GDSC1; GDSC2; CTRP2; CTRP1 -8.2889 -7.6389 -8.2889 35.7499
MM1.S GDSC2 -8.2802 -6.8607 -8.3016 26.5642
EB1 CTRP2 -8.2677 -6.8667 -8.268 35.6091
GA-10 GDSC1; GDSC2; CTRP2 -8.2573 -6.5936 -8.2586 35.5428
LP-1 GDSC1; GDSC2; CTRP2; CTRP1 -8.2416 -7.653 -8.2416 35.4336
Karpas-299 GDSC1; GDSC2; CTRP2 -8.2224 -7.5072 -8.2224 35.3049
CML-T1 GDSC2; CTRP2 -8.2163 -7.2356 -8.2163 35.2644
MHH-CALL-2 GDSC2 -8.2072 -7.2671 -8.2093 25.7339
RL GDSC1; GDSC2; CTRP2 -8.2051 -7.3163 -8.2051 35.1892
Jiyoye GDSC1; GDSC2 -8.2045 -7.3215 -8.2059 25.7033
OCI-Ly7 GDSC2 -8.1886 -7.3106 -8.19 25.5441
LAMA-84 GDSC1; GDSC2; CTRP2 -8.1853 -6.7259 -8.1858 35.0584
HEL GDSC1; GDSC2; CTRP2 -8.1812 -7.5065 -8.1812 35.0296
SKM-1 GDSC1; GDSC2; CTRP2; CTRP1 -8.1394 -7.5807 -8.1394 34.7496
SR GDSC1; GDSC2; CTRP2 -8.137 -7.5173 -8.137 34.7337
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 -8.1107 -6.0447 -8.1184 34.5834
SUP-M2 GDSC1; GDSC2 -8.1106 -7.611 -8.1106 24.754
U266B1 GDSC1; GDSC2; CTRP2 -8.1104 -7.0656 -8.1104 34.4739
DEL GDSC1; GDSC2; CTRP2 -8.1076 -7.2771 -8.1076 34.5375
SU-DHL-1 GDSC1; GDSC2; CTRP2 -8.0999 -7.31 -8.0999 34.4859
ST486 GDSC1; GDSC2; CTRP2 -8.0945 -7.3741 -8.0945 34.4498
Granta-519 GDSC1; GDSC2; CTRP2 -8.0737 -7.0536 -8.0737 34.3105
KMS-12-BM GDSC2; CTRP2 -8.0645 -7.3024 -8.0645 34.2487
Raji GDSC1; GDSC2; CTRP2 -8.0578 -7.169 -8.0578 34.2045
CMK CTRP2 -8.0445 -7.1545 -8.0445 34.1153
MEG-01 GDSC1; GDSC2 -8.0384 -6.0211 -8.1646 24.6824
SUP-B8 GDSC2 -8.0366 -7.0386 -8.0412 24.0347
KM-H2 GDSC1; GDSC2; CTRP2 -7.9869 -7.1413 -7.9869 33.7298
MOLT-13 GDSC2; CTRP2 -7.9694 -7.1276 -7.9694 33.6132
RC-K8 GDSC1; GDSC2 -7.9687 -6.4575 -8.014 23.5608
BONNA-12 GDSC2 -7.9446 -6.3929 -7.9969 23.3555
NCO2 CTRP2 -7.9329 -6.478 -7.9336 33.3714
HL-60 GDSC1; GDSC2; CTRP2 -7.9132 -6.9258 -7.9132 33.2372
KO52 CTRP2 -7.9057 -6.7264 -7.9058 33.187
MOLM-13 GDSC1; GDSC2; CTRP2 -7.9004 -5.3983 -7.9293 33.2474
BC-1 GDSC1; GDSC2 -7.8954 -5.2825 -8.2084 24.2496
Ku812 GDSC1; GDSC2; CTRP2; CTRP1 -7.8897 -5.4244 -7.8897 56.4084
VAL GDSC1; GDSC2 -7.8892 -4.595 -8.4435 25.4816
CTB-1 GDSC1; GDSC2 -7.8866 -5.5424 -8.1199 23.7332
BV-173 GDSC1; GDSC2; CTRP2 -7.8716 -7.0314 -7.8716 32.9591
HuT 78 CTRP2 -7.8665 -6.4782 -7.867 32.8483
OCI-AML-2 GDSC1; GDSC2; CTRP2 -7.8599 -7.1407 -7.8599 32.8806
SU-DHL-8 GDSC1; GDSC2; CTRP2 -7.8507 -6.7143 -7.8508 32.8196
NALM-6 GDSC1; GDSC2; CTRP2 -7.8074 -6.4057 -7.808 32.5317
KCL-22 GDSC1; GDSC2; CTRP2 -7.7831 -6.8547 -7.7831 32.3672
Karpas-422 GDSC1; GDSC2; CTRP2 -7.7734 -7.1424 -7.7734 32.3019
MV4-11 GDSC1; GDSC2; CTRP2 -7.7661 -6.143 -7.7683 32.2608
NB4 GDSC1; GDSC2; CTRP2 -7.7445 -7.102 -7.7445 32.1086
SU-DHL-5 GDSC2; CTRP1 -7.7376 -7.3094 -7.7376 37.8527
KMS-27 CTRP2 -7.7303 -6.231 -7.7315 32.018
HDLM-2 GDSC1; GDSC2; CTRP2 -7.7259 -6.4274 -7.7263 31.9857
ALL-PO GDSC1; GDSC2 -7.7259 -6.2059 -7.791 21.2279
ROS-50 GDSC1; GDSC2 -7.7193 -6.2939 -7.7702 21.0877
U-937 CTRP2; CTRP1 -7.7189 -7.0395 -7.7189 34.1835
SU-DHL-4 GDSC1; GDSC2; CTRP2; CTRP1 -7.7009 -7.1562 -7.7009 31.817
RPMI-8866 GDSC1 -7.671 -6.4871 -7.6955 25.4942
Kasumi-2 CTRP2 -7.6665 -6.6495 -7.6666 31.5125
JeKo-1 GDSC2; CTRP2 -7.6508 -7.1413 -7.6508 31.4822
SK-MM-2 GDSC1; GDSC2; CTRP2 -7.6304 -5.5346 -7.6443 31.3924
KYO-1 CTRP2 -7.6206 -6.1362 -7.622 31.2849
Hs 611.T CTRP2 -7.6204 -5.984 -7.6232 31.2881
F-36P CTRP2 -7.6173 -6.3157 -7.6178 31.1857
WSU-DLCL2 GDSC1; GDSC2; CTRP2; CTRP1 -7.6113 -6.6106 -7.6114 31.2184
P12-Ichikawa GDSC2; CTRP2 -7.5917 -6.8271 -7.5917 31.0872
HEL 92.1.7 CTRP2 -7.5871 -6.6516 -7.5872 31.0565
MOLM-6 CTRP2 -7.578 -5.8245 -7.5828 31.0116
JURL-MK1 GDSC1; CTRP2 -7.5554 -5.0819 -7.5922 30.9673
MOLP-8 GDSC1; GDSC2; CTRP2 -7.5411 -6.6497 -7.5411 30.7486
Mino CTRP2 -7.523 -7.0337 -7.523 30.6273
MOLM-16 GDSC2; CTRP2; CTRP1 -7.5103 -6.8429 -7.5103 30.5427
Ri-1 CTRP2 -7.4919 -6.0706 -7.4931 30.4235
KMS-26 CTRP2 -7.4905 -6.8312 -7.4905 30.4102
KMS-34 CTRP2 -7.4855 -6.4066 -7.4856 30.3773
SIG-M5 GDSC1; GDSC2; CTRP2 -7.4805 -7.0077 -7.4805 30.343
RPMI-6666 GDSC1; GDSC2; CTRP2 -7.4698 -6.3795 -7.4699 30.2718
DG-75 GDSC1; GDSC2 -7.4673 -6.208 -7.513 18.5321
Ki-JK CTRP2 -7.4134 -6.2708 -7.4136 29.8955
KMS-18 CTRP2 -7.4053 -4.9586 -7.4451 29.974
SET-2 CTRP2 -7.3998 -6.6734 -7.3998 29.8034
OCI-Ly3 CTRP2 -7.3745 -6.6164 -7.3745 29.6344
MHH-CALL-4 GDSC2; CTRP2 -7.373 -6.5499 -7.373 29.6241
HD-MY-Z CTRP2 -7.3471 -6.0374 -7.3479 29.4537
EHEB GDSC1; CTRP2 -7.3467 -5.6441 -7.352 29.4663
U-698-M GDSC1; GDSC2 -7.3331 -2.3517 -8.8464 25.2059
KHM-1B CTRP2 -7.3321 -5.7752 -7.335 29.3604
M-07e CTRP2 -7.2957 -6.1521 -7.2959 29.039
KE-97 CTRP2; CTRP1 -7.2849 -6.6747 -7.2849 53.7742
L-363 GDSC1; GDSC2; CTRP2 -7.24 -6.6533 -7.24 28.7351
HAL-01 GDSC1; GDSC2 -7.2279 -4.4813 -7.7863 18.9928
NU-DHL-1 CTRP2 -7.2256 -5.0297 -7.2528 28.6617
Kasumi-1 GDSC1; GDSC2; CTRP2 -7.1979 -5.8199 -7.1994 28.4583
TF-1 CTRP2 -7.1811 -6.5247 -7.1811 28.341
MLMA GDSC1; GDSC2 -7.1584 -5.2177 -7.4301 16.6656
L-428 GDSC1; GDSC2; CTRP2 -7.1373 -5.8675 -7.1381 27.9841
SCC-3 GDSC1; GDSC2 -7.1195 -4.1267 -7.8236 18.7661
MHH-PREB-1 GDSC1; GDSC2 -7.1098 -5.9542 -7.1709 15.0261
GDM-1 GDSC1; GDSC2; CTRP2; CTRP1 -7.0117 -4.295 -7.1005 27.5088
EoL-1 GDSC1; GDSC2; CTRP2 -6.9917 -4.3734 -7.0689 27.3355
SU-DHL-10 GDSC2; CTRP2 -6.8072 -5.7846 -6.8074 25.8408
PL21 CTRP2; CTRP1 -6.7298 -5.5584 -6.7307 25.3258
NOMO-1 GDSC1; GDSC2; CTRP1 -6.7155 -4.7639 -6.7406 29.8817
KMS-20 CTRP2 -6.7112 -5.5411 -6.7121 25.1413
Ci-1 CTRP2 -6.6426 -5.9721 -6.6426 24.7396
JVM-2 GDSC1; GDSC2; CTRP2 -6.5878 -3.3847 -6.8095 25.1383
KMS-28BM CTRP2 -6.5856 -3.8442 -6.7135 24.7957
Jurkat GDSC2; CTRP2 -6.5555 -5.7374 -6.5555 24.1571
HPB-ALL CTRP2 -6.5237 -5.4662 -6.5243 23.9465
EB2 GDSC1; GDSC2 -6.5159 -3.5166 -7.4997 14.5406
JVM-3 GDSC1; GDSC2; CTRP2 -6.5005 -4.9687 -6.509 23.8178
IM-9 GDSC1; GDSC2 -6.4972 -3.4752 -7.5015 14.4841
ME1 CTRP2 -6.492 -4.403 -6.5364 23.8825
WSU-NHL GDSC1; GDSC2 -6.4515 -3.6178 -7.3893 13.6367
MN-60 GDSC1; GDSC2 -6.4331 -4.0695 -7.1572 12.1512
K-562 GDSC1; GDSC2; CTRP2 -6.3446 -5.0728 -6.3478 22.7572
DoHH2 GDSC1; GDSC2 -6.1317 -4.4205 -6.6979 8.242
Reh GDSC1; GDSC2; CTRP2 -6.0835 -5.0602 -6.0846 21.0043
YT GDSC1; GDSC2 -6.037 -3.1232 -7.2451 11.3325
P3HR-1 CTRP2; CTRP1 -5.9965 -4.9545 -5.9965 48.1615
MC116 GDSC1; GDSC2; CTRP2; CTRP1 -5.9958 -1.9021 -6.0057 48.1665
SUP-T1 GDSC1; GDSC2; CTRP2 -5.9769 -3.6606 -6.0893 20.673
P30/OHK GDSC1; GDSC2 -5.9149 -3.9699 -6.7162 7.6212
TUR GDSC1; GDSC2 -5.889 -2.2751 -7.5366 12.6712
RCH-ACV GDSC2; CTRP2 -5.8785 -4.3883 -5.8962 19.6891
GR-ST GDSC1; GDSC2 -5.854 -3.3449 -6.9728 9.0435
OCI-AML-5 GDSC1; CTRP2 -5.8421 -4.8332 -5.8437 19.3453
Mono-Mac-1 CTRP2 -5.8075 -2.6606 -6.1506 20.3684
KY821 GDSC1; GDSC2 -5.6433 3.07 -10.0003 24.4806
THP-1 GDSC1; GDSC2; CTRP2; CTRP1 -5.5856 -4.2256 -5.6027 18.9748
P31/FUJ GDSC1; GDSC2; CTRP2 -5.5521 -4.6958 -5.5531 17.4496
AML-193 CTRP2 -5.5374 -2.5214 -5.8999 18.5946
SUP-T11 CTRP2 -5.2028 -3.0104 -5.3911 15.7697
OCI-Ly10 CTRP1 -4.9541 -3.2807 -5.0557 29.4581
Mono-Mac-6 GDSC1; GDSC2; CTRP2 -3.6655 3.9231 -6.9955 18.1787
CA46 GDSC1; GDSC2 -3.6267 3.4984 -8.6627 13.1857
MHH-CALL-3 CTRP2 -3.0994 -0.5175 -4.2887 5.9863
REC-1 CTRP2 -1.467 1.1255 -3.919 1.9855
KMM-1 CTRP2 0.4891 10.1001 -6.8742 10.5612
Karpas-620 GDSC2; CTRP2 0.778 2.4943 -3.4882 0.0444
⏷ Show the Full List of 218 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 -6.6489 -4.8712 -6.6654 24.8371
TE15 CTRP2 -6.1297 -3.8723 -6.2182 21.6116
TE-8 GDSC1; GDSC2 -10.3887 -9.525 -10.3887 47.615
TE-15 GDSC1 -8.3512 -5.9695 -8.5163 34.8103
TE-5 GDSC1; GDSC2; CTRP2 -8.12 -6.3637 -8.1224 34.628
T.T GDSC2 -7.9612 -6.8816 -7.9699 23.2982
KYSE-270 GDSC2 -7.604 -6.3227 -7.6431 19.8693
TE-9 GDSC1; GDSC2; CTRP2 -7.5536 -6.7054 -7.5536 30.8324
KYSE-30 CTRP2 -7.3607 -6.2123 -7.3609 29.4725
TE-1 GDSC1; GDSC2; CTRP2 -7.3198 -6.0618 -7.3228 26.1685
TE-10 GDSC1; GDSC2; CTRP2 -7.3055 -5.3025 -7.3206 29.2235
OE33 GDSC2; CTRP2 -7.0471 -6.0931 -7.0472 27.445
TE-4 GDSC2; CTRP2 -6.8813 -3.9684 -7.0107 26.7772
OE21 GDSC2; CTRP2 -6.8166 -5.1369 -6.8262 25.9356
KYSE-520 GDSC2; CTRP2 -6.7551 -5.1578 -6.7627 25.5173
KYSE-410 GDSC2; CTRP2; CTRP1 -6.7032 -5.0171 -6.7032 51.2402
KYSE-510 GDSC2; CTRP2 -6.5288 -5.8721 -6.5288 23.9216
KYSE-150 GDSC2; CTRP2 -6.5202 -5.3179 -6.5217 23.8691
KYSE-70 GDSC2; CTRP2 -6.1351 -3.3735 -6.5063 18.5705
KYSE-180 GDSC2; CTRP2 -5.9836 -5.1458 -5.9839 20.3331
KYSE-450 GDSC2; CTRP2; CTRP1 -5.9327 -4.2433 -5.9327 47.8835
TE-11 GDSC2; CTRP2 -5.5077 -3.4808 -5.6156 17.5211
OE19 GDSC2; CTRP2 -5.4709 -2.6666 -5.782 18.0065
COLO 680N GDSC2; CTRP2 -5.2393 -3.2181 -5.3797 15.8418
TE-6 GDSC1; GDSC2; CTRP2 -5.1787 -1.6432 -5.8296 17.3406
TE-14 CTRP2 -5 -3.153 -5.1342 14.1871
KYSE-140 GDSC2; CTRP2; CTRP1 -4.5698 -2.0753 -4.5703 41.9471
EC-GI-10 GDSC1; GDSC2; CTRP2 -4.3964 0.658 -6.0628 16.234
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 -5.4742 -3.235 -5.6315 17.4717
PaTu 8988t GDSC2; CTRP2 -8.2321 -4.3555 -8.4 35.8954
KP-1N GDSC2 -7.8718 -6.5351 -7.9023 22.5123
MZ-PC-1 GDSC1; GDSC2 -7.8529 -5.2436 -8.1747 23.8741
SW1990 GDSC2; CTRP2 -7.6543 -6.3796 -7.6547 31.5069
HuP-T3 GDSC2; CTRP2 -7.0955 -5.2887 -7.106 27.8035
PSN1 GDSC1; GDSC2; CTRP2 -7.02 -5.9084 -7.0204 27.2648
DAN-G GDSC2; CTRP2 -6.9845 -5.2493 -6.9939 27.0576
Panc 10.05 GDSC2; CTRP2; CTRP1 -6.9032 -4.5131 -6.9032 52.0304
Capan-1 GDSC2 -6.8485 -5.4589 -7.0134 12.9698
QGP-1 GDSC2; CTRP2; CTRP1 -6.7137 -3.9776 -6.7139 51.2857
PaTu 8902 GDSC2; CTRP2; CTRP1 -6.6894 -5.3103 -6.6894 53.4682
Panc 08.13 GDSC2; CTRP2 -6.6716 -5.3277 -6.6743 24.8832
BxPC-3 GDSC2; CTRP2 -6.6373 -5.3124 -6.6399 24.7129
PL4 GDSC2 -6.5888 -4.334 -7.1899 12.9327
YAPC GDSC2; CTRP2 -6.366 -5.3552 -6.3705 18.8336
Hs 766T GDSC2; CTRP2 -6.354 -3.2315 -6.5909 23.5758
KP-4 GDSC2; CTRP2 -6.3536 -4.4903 -6.3835 22.9074
KP-3 GDSC2; CTRP2; CTRP1 -6.3351 -3.7089 -6.3353 49.6366
HPAF-II GDSC2; CTRP2 -6.28 -4.9851 -6.284 22.3279
Panc 03.27 GDSC2; CTRP2; CTRP1 -6.2679 -5.1413 -6.2679 49.3436
HPAC GDSC2; CTRP2; CTRP1 -6.2649 -0.6892 -6.3228 51.4962
Panc 02.03 GDSC2; CTRP2 -6.0043 -3.4535 -6.1597 21.0076
CFPAC-1 GDSC2; CTRP2; CTRP1 -6.0027 -5.0186 -6.0027 48.1885
MIA PaCa-2 GDSC2; CTRP2 -5.9417 -4.9519 -5.9428 20.0556
SNU-213 CTRP2 -5.8472 -4.5939 -5.8541 19.4432
SU.86.86 GDSC2; CTRP2 -5.8328 -4.5077 -5.8427 19.3569
KP-2 GDSC2; CTRP2 -5.81 -2.8501 -6.0978 20.1837
Panc 04.03 GDSC2; CTRP2 -5.6036 -2.8868 -5.8622 18.7001
PaTu 8988s CTRP2 -5.5704 -2.1559 -6.0583 19.3243
HuP-T4 GDSC2; CTRP2; CTRP1 -5.114 -2.8816 -5.1141 46.2983
PK-59 CTRP2 -4.7314 -3.7969 -4.8423 6.6891
PK-45H CTRP2 -4.589 -1.9747 -5.0727 12.786
L3.3 CTRP2 -4.3306 -3.4474 -4.5493 4.1043
SUIT-2 GDSC2; CTRP2; CTRP1 -4.2435 -2.1424 -4.2436 40.5249
Panc 05.04 CTRP2 -4.2068 -3.1834 -4.5488 3.7491
AsPC-1 GDSC2; CTRP2 -3.8092 3.6087 -6.9663 18.385
Capan-2 GDSC2; CTRP2; CTRP1 -3.3798 1.9082 -3.52 36.9898
SNU-410 CTRP2 0.3708 2.26 -3.5484 0.1205
TCC-Pan2 CTRP2 0.5057 3.0376 -4.7324 0.1882
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 76 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 -7.2013 -5.6087 -7.2053 32.7982
SH-4 GDSC1; GDSC2 -12.1689 -10.0964 -12.1708 65.2457
MMAc-SF GDSC1; GDSC2 -12.0838 -10.5629 -12.084 64.5839
A-388 GDSC1; GDSC2 -11.0048 -9.3363 -11.0061 53.7866
MZ-MEL-2 GDSC1; GDSC2 -10.9442 -8.9412 -10.9497 53.1624
LB2518-MEL GDSC1; GDSC2 -10.8748 -10.2502 -10.8748 52.4926
LB373-MEL-D GDSC1; GDSC2 -10.765 -9.2354 -10.7659 51.3888
CP66-MEL GDSC1; GDSC2 -10.6335 -9.6707 -10.6335 50.0713
IST-MEL1 GDSC1; GDSC2 -10.2699 -8.9716 -10.2703 46.424
MZ-MEL-7 GDSC1; GDSC2 -9.7386 -7.429 -9.7805 41.2639
A101D GDSC1; GDSC2; CTRP2 -9.4803 -6.8514 -9.4904 43.7444
CP50-MEL-B GDSC2 -8.5176 -7.2396 -8.5258 28.8795
WM35 GDSC2 -8.48 -7.3235 -8.4848 28.4853
DJM-1 GDSC1; GDSC2 -8.2531 -5.8476 -8.4384 27.14
G-mel GDSC2 -8.2365 -7.0435 -8.2455 26.0628
A-431 GDSC2 -8.2218 -6.4773 -8.2812 26.1727
WM278 GDSC2 -8.1324 -4.8121 -8.6249 27.537
VMRC-MELG GDSC2 -8.121 -6.8891 -8.1344 24.9258
COLO 783 GDSC2 -7.9951 -5.1545 -8.3584 25.5095
Hs 938.T GDSC2 -7.9595 -7.324 -7.9597 23.2388
Hs 294T CTRP2 -7.9488 -7.1592 -7.9488 33.4753
GAK GDSC2 -7.9176 -7.0705 -7.9197 22.8275
M14 GDSC2 -7.819 -5.8856 -7.9563 22.5419
COLO 792 GDSC2; CTRP2 -7.818 -5.6727 -7.8312 32.6444
G-361 GDSC2; CTRP2; CTRP1 -7.7315 -4.7993 -7.7317 58.2049
COLO 679 GDSC2 -7.6832 -6.2391 -7.7398 20.7551
K029AX CTRP2 -7.6742 -6.9526 -7.6742 31.6386
HMV-II GDSC2 -7.6714 -5.0054 -8.0588 22.4271
HT-144 GDSC1; GDSC2; CTRP2 -7.5387 -5.9656 -7.541 30.7404
451Lu GDSC2 -7.3323 -5.571 -7.5069 17.867
WM88 CTRP2 -7.3185 -5.3653 -7.3314 29.3031
WM115 GDSC2; CTRP2 -7.2573 -6.0094 -7.2578 28.8523
SK-MEL-5 GDSC2; CTRP2; CTRP1 -7.206 -5.3783 -7.2158 30.547
COLO 829 GDSC1; GDSC2; CTRP2 -7.1764 -3.8801 -7.3452 28.8819
RVH-421 GDSC2; CTRP2 -7.107 -5.926 -7.1074 27.8466
CHL-1 GDSC2 -7.0925 -4.9599 -7.4528 16.5105
WT2-iPS GDSC2; CTRP2 -7.0606 -6.0234 -7.0607 27.5355
RPMI-7951 GDSC2; CTRP2 -7.0384 -5.2659 -7.0484 27.4202
IPC-298 GDSC2; CTRP2 -6.9786 -5.8527 -6.9813 23.5414
Mel Ho GDSC2; CTRP2 -6.9331 -5.6985 -6.934 26.6855
COLO 800 GDSC1; GDSC2; CTRP2 -6.8621 -4.4247 -6.9252 26.4211
HMCB CTRP2 -6.8477 -5.398 -6.8513 26.1234
SK-MEL-28 GDSC2; CTRP2; CTRP1 -6.8409 -3.813 -6.9949 28.4583
MeWo GDSC2; CTRP2 -6.8177 -5.3356 -6.822 25.9247
SK-MEL-2 GDSC1; GDSC2; CTRP2 -6.7927 -4.6153 -6.8326 25.8782
WM793 GDSC2; CTRP2 -6.7685 -5.5766 -6.7742 21.9357
LOX-IMVI GDSC1; GDSC2; CTRP2 -6.6579 -3.99 -6.7669 25.2137
UACC-257 GDSC1; GDSC2; CTRP2 -6.5292 -4.5395 -6.5631 24.0954
Hs 852.T CTRP2; CTRP1 -6.4785 -5.3913 -6.4785 52.5084
COLO 741 CTRP2; CTRP1 -6.4656 -2.0285 -6.479 50.2038
WM266-4 CTRP2 -6.4108 -4.598 -6.4351 23.2708
A2058 GDSC2; CTRP2 -6.4001 -4.8633 -6.41 23.151
IGR-39 CTRP2 -6.3169 -3.6438 -6.4602 23.054
IGR-37 GDSC2; CTRP2 -6.2861 -5.5549 -6.2861 22.3023
SK-MEL-30 GDSC2; CTRP2 -6.2698 -5.6147 -6.27 18.076
A-375 GDSC2; CTRP2; CTRP1 -6.2219 -4.8092 -6.2297 21.9522
WM1552C GDSC2 -6.2042 -4.9898 -6.5058 7.3402
UACC-62 GDSC2; CTRP2 -6.1587 -4.714 -6.1685 21.5363
WM983B CTRP2 -6.0756 -4.6057 -6.0878 20.9886
SK-MEL-31 GDSC2; CTRP2 -6.0164 -4.0405 -6.1764 16.7681
CJM [Human melanoma] CTRP2 -5.847 -4.3711 -5.8646 19.4781
IGR-1 GDSC2; CTRP2 -5.835 -4.4332 -5.8486 19.3843
Mel JuSo GDSC2; CTRP2 -5.7838 -4.3821 -5.7985 19.0455
Hs 944.T CTRP2; CTRP1 -5.6029 -3.9309 -5.6029 46.4468
SK-MEL-24 GDSC2 -5.3876 0.3682 -8.4391 16.4414
Hs 940.T GDSC2; CTRP2 -5.0851 -2.0077 -5.5894 16.1211
WM1799 CTRP2 -4.7926 -4.0477 -4.8409 6.8977
Hs 895.T CTRP2 -4.7605 -3.0797 -4.891 12.6071
SK-MEL-3 GDSC2; CTRP2 -4.7255 -0.7228 -5.747 15.7977
MDA-MB-435S CTRP2 -4.6144 -3.8767 -4.6903 5.6424
SK-MEL-1 GDSC1; GDSC2; CTRP2; CTRP1 -4.3152 -1.0542 -5.1823 12.4905
Hs 936.T CTRP2; CTRP1 -4.2713 -1.634 -4.2724 42.4653
Malme-3M CTRP2 -2.609 3.5487 -5.9151 11.7992
Hs 839.T CTRP2 0.2846 6.7817 -5.4518 5.6813
Hs 688(A).T CTRP2 0.3079 1.8642 -3.438 0.0477
EquiPSC Line K2 GDSC2 -7.3329 -5.6243 -7.4925 17.7913
⏷ Show the Full List of 76 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OACM5.1 C GDSC2 -7.9325 -5.4981 -8.1829 24.283
HCE-4 GDSC2 -7.8842 -6.8663 -7.8915 22.5184
KYSE-220 GDSC2 -7.5838 -6.0539 -7.6648 19.8858
KYAE-1 GDSC2 -7.494 -5.7052 -7.6466 19.3673
ESO-51 GDSC2 -7.32 -5.6316 -7.4765 17.6452
OACP4 C GDSC2 -7.3019 -5.656 -7.45 17.4182
TE-12 GDSC1; GDSC2 -7.2858 -5.4025 -7.5071 17.6584
SK-GT-4 GDSC2 -6.7772 -4.8877 -7.1459 13.42
FLO-1 GDSC2 -6.6362 -4.2118 -7.2931 13.7343
KYSE-50 GDSC2 -6.5801 -4.5957 -7.0643 12.1461
ESO-26 GDSC2 -6.0306 -5.0717 -6.293 5.3929
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 -6.076 -1.8445 -6.7146 23.2339
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GI-ME-N GDSC1; GDSC2 -9.856 -8.7643 -9.8562 42.2702
SJNB-12 GDSC1; GDSC2 -9.017 -7.3171 -9.0365 33.9464
Kelly GDSC1; GDSC2; CTRP2 -8.9365 -7.8287 -8.9365 40.0805
NB69 GDSC1; GDSC2 -8.93 -7.9579 -8.9305 32.9791
LA-N-6 GDSC1; GDSC2 -8.7625 -6.7831 -8.8173 31.5703
SJNB-13 GDSC1; GDSC2 -8.7335 -7.3148 -8.7442 31.0583
SK-N-MC-IXC GDSC2 -8.2421 -7.3215 -8.2438 26.0823
NB(TU)1 GDSC1; GDSC2 -8.165 -6.7032 -8.1944 25.4491
CHP-134 GDSC2 -7.9311 -7.1431 -7.9323 22.9587
SK-N-SH GDSC2; CTRP2 -7.8994 -5.3483 -7.9315 33.2513
SK-N-AS GDSC2 -7.8993 -6.3643 -7.9525 22.9055
SJNB-5 GDSC1; GDSC2 -7.7664 -5.9642 -7.8814 21.8966
CHP-212 GDSC2 -7.7221 -6.2041 -7.7871 21.1892
SJNB-17 GDSC1; GDSC2 -7.6702 -5.0194 -8.0525 22.3871
SJNB-14 GDSC1; GDSC2 -7.479 -6.6188 -7.4861 18.4514
CHP-126 GDSC1; GDSC2; CTRP2 -7.3946 -5.6383 -7.4007 29.7891
IMR-32 CTRP2 -7.3514 -6.9189 -7.3514 29.4801
NB1 GDSC1; GDSC2; CTRP2 -7.2925 -6.0754 -7.2929 29.0871
SK-N-BE(2)-M17 GDSC1; GDSC2 -7.2461 -5.7366 -7.368 16.7178
SJNB-7 GDSC1; GDSC2 -7.1889 -6.0507 -7.2389 15.762
KP-N-SI9s CTRP2 -7.1621 -6.0619 -7.1624 28.2148
TGW GDSC1; GDSC2 -7.0643 -6.0421 -7.1062 14.4692
SK-N-DZ GDSC1; GDSC2 -6.8974 -3.4555 -7.9016 18.3516
SK-N-FI GDSC1; GDSC2; CTRP2 -6.8732 -5.3375 -6.8782 26.2986
SJNB-10 GDSC1; GDSC2 -6.8689 -4.2087 -7.5305 16.052
KP-N-RT-BM-1 GDSC2 -6.8347 -4.9136 -7.1963 13.9505
SiMa GDSC1; GDSC2; CTRP2 -6.7122 -4.9116 -6.7285 25.2597
MHH-NB-11 GDSC1; GDSC2; CTRP2 -6.6064 -4.5935 -6.6394 24.6088
NH-6 CTRP2 -6.4261 -4.3081 -6.4768 23.4634
SJNB-6 GDSC1; GDSC2 -6.3152 -4.745 -6.728 9.1032
GOTO GDSC1; GDSC2 -6.2639 -2.9873 -7.5186 13.7761
IMR-5 GDSC1; GDSC2 -6.2178 -2.3167 -7.807 15.3714
NH-12 GDSC1; GDSC2 -6.0166 -3.4506 -7.0648 10.139
KP-N-YS GDSC1; GDSC2 -5.8697 -2.3028 -7.5061 12.424
SK-N-BE(2) CTRP2 -5.6207 -2.737 -5.9241 18.9326
KP-N-YN GDSC1; GDSC2; CTRP2 -1.6604 7.6322 -7.2038 15.0371
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2; CTRP2 -7.5131 -6.4419 -7.5132 30.5619
SNU-478 CTRP2 -7.4207 -6.2487 -7.421 29.9443
SNU-1079 CTRP2 -6.7154 -2.9716 -7.0522 26.392
HuH-28 CTRP2 -6.6014 -5.7876 -6.6014 24.4639
SNU-308 CTRP2 -5.9355 -4.9359 -5.9368 20.0151
SNU-869 CTRP2 -5.3109 -2.028 -5.8243 17.6948
SNU-1196 CTRP2 -4.7113 -1.9206 -5.2239 13.709
SNU-245 CTRP2 -3.9963 -0.8104 -4.9776 10.841
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OCUB-M GDSC1; GDSC2 -9.678 -6.4964 -9.8464 40.9746
HCC70 GDSC2 -8.5482 -7.4413 -8.5514 29.0593
DU4475 GDSC1; GDSC2; CTRP2 -8.3717 -6.591 -8.3737 36.3103
MFM-223 GDSC1; GDSC2 -8.3059 -6.0769 -8.4433 27.3232
HCC1569 GDSC2 -8.2183 -7.1907 -8.2221 25.7635
HCC38 GDSC2; CTRP2 -8.1922 -7.1399 -8.1922 35.1029
Evsa-T GDSC1; GDSC2 -8.1892 -6.9092 -8.2037 25.5262
HCC202 CTRP2 -8.0328 -6.0376 -8.0394 34.0589
MDA-MB-436 GDSC2 -7.9961 -5.6864 -8.1994 24.5804
HCC1187 GDSC1; GDSC2 -7.9217 -6.6662 -7.9426 22.8838
CAL-120 GDSC2 -7.8364 -5.8344 -7.9874 22.7096
HCC2157 GDSC1; GDSC2 -7.7923 -6.7637 -7.8017 21.5315
Hs 578T GDSC2; CTRP2 -7.7505 -5.9673 -7.7548 32.1632
MDA-MB-468 GDSC2; CTRP2 -7.7341 -6.3575 -7.7347 32.0415
HCC1937 GDSC2; CTRP2 -7.6044 -5.5492 -7.6172 31.2147
MDA-MB-175-VII GDSC2 -7.5996 -5.1665 -7.9253 21.2973
EFM-19 GDSC2 -7.458 -5.5433 -7.652 19.1645
HCC1500 GDSC1; GDSC2; CTRP2 -7.4505 -5.3222 -7.4688 30.2042
JIMT-1 GDSC2; CTRP2 -7.3837 -5.3568 -7.3986 29.7457
CAL-51 GDSC2; CTRP2 -7.2564 -5.1572 -7.2771 28.9143
BT-549 GDSC2; CTRP2 -7.1239 -5.0104 -7.1485 28.0413
SK-BR-3 CTRP2 -7.033 -5.2876 -7.0422 27.3162
MRK-nu-1 GDSC1; GDSC2 -6.9409 -5.0478 -7.2574 14.6968
HCC1599 GDSC1; GDSC2 -6.9347 -4.0813 -7.6541 16.9815
HCC1954 GDSC2; CTRP2 -6.9016 -5.4973 -6.9042 26.4806
CAMA-1 GDSC2; CTRP2 -6.8722 -5.0917 -6.8848 26.3175
HCC1806 GDSC2; CTRP2 -6.8571 -4.9314 -6.8771 26.2413
T-47D GDSC2; CTRP2 -6.7881 -4.8014 -6.8135 25.7369
HMC-1-8 CTRP2 -6.6454 -5.9372 -6.6454 24.7583
CAL-85-1 GDSC2; CTRP2 -6.5939 -4.4188 -6.6422 24.5771
MDA-MB-231 GDSC2; CTRP2 -6.591 -4.8157 -6.6085 24.4532
HCC1419 GDSC2; CTRP2 -6.4912 -4.0011 -6.5862 24.0511
COLO 824 GDSC1; GDSC2 -6.4838 -3.3551 -7.5462 14.6576
EFM-192A GDSC2; CTRP2 -6.4492 -2.3256 -6.9543 25.2201
MDA-MB-453 GDSC2; CTRP2 -6.4022 -3.6594 -6.5495 23.5818
UACC-812 GDSC1; GDSC2 -6.3234 -4.2758 -6.9527 10.4633
HCC1143 GDSC2; CTRP2 -6.2025 -2.8767 -6.7577 19.8791
AU565 GDSC2; CTRP2 -5.993 -2.7119 -6.3375 21.5587
MDA-MB-157 GDSC2; CTRP2 -5.9733 -1.8453 -6.6037 22.4723
HCC2218 GDSC1; GDSC2 -5.9184 -3.3388 -7.0325 9.5878
MDA-MB-361 GDSC2; CTRP2 -5.5867 -1.3157 -7.7605 10.7064
BT-20 GDSC2; CTRP2 -5.5309 -4.3315 -5.5403 17.3363
HCC1395 GDSC2; CTRP2 -5.4765 -3.1272 -5.6599 17.5801
HDQ-P1 GDSC2; CTRP2 -5.4141 -1.9986 -5.9461 18.4507
YMB-1-E GDSC2 -5.0556 -1.9922 -7.0056 7.0479
UACC-893 GDSC2 -4.7271 0.4375 -7.9584 11.9278
MDA-MB-330 GDSC2 -4.6572 0.9109 -8.1397 12.7799
CAL-148 GDSC1; GDSC2; CTRP2 -4.1226 -1.0532 -4.9894 11.227
ZR-75-30 GDSC2; CTRP2 -3.8209 1.0622 -5.7175 13.4981
HCC1428 GDSC2; CTRP2 -3.5078 2.4706 -6.134 14.5061
BT-474 GDSC1; GDSC2; CTRP2 -3.2322 0.5428 -4.9327 8.947
MCF-7 GDSC2; CTRP2; CTRP1 -2.8992 1.8832 -5.32 9.9279
MDA-MB-415 GDSC2; CTRP2 -2.3384 0.2385 -4.0626 3.6627
BT-483 GDSC2 -1.0648 10.846 -10.4563 15.815
ZR-75-1 CTRP2 -0.6316 1.7863 -4.7115 0.4157
KPL-1 CTRP2 -0.1446 1.0932 -3.3359 0.0301
Hs 578Bst CTRP2 -0.0271 6.2499 -5.3968 5.8286
BT 228 CTRP2 -8.7842 -8.1136 -8.7842 38.9691
BT 145 CTRP2 -8.3116 -7.8076 -8.3116 35.9015
BT164 CTRP2 -8.2753 -7.6677 -8.2753 35.6587
BT 131 CTRP2 -8.2139 -7.2568 -8.2139 35.1643
BT 112 CTRP2 -8.0321 -7.4031 -8.0321 34.0325
BT 330 CTRP2 -7.4758 -6.7851 -7.4758 30.2398
BT 248 CTRP2 -7.4257 -6.1514 -7.4262 29.9072
BT 416 CTRP2 -7.3325 -2.2443 -7.941 31.2886
BT 216 CTRP2 -7.3263 -6.3193 -7.3264 29.2425
BT 271 CTRP2 -7.2928 -6.1745 -7.293 29.0197
BT 286 CTRP2 -7.2461 -6.3654 -7.2461 28.7073
BT 231 CTRP2 -7.0094 -5.3376 -7.0167 27.1524
BT 422 CTRP2 -6.9827 -4.9989 -7.003 27.018
BT 359 CTRP2 -6.9786 -5.7507 -6.9795 26.9255
BT 428 CTRP2 -6.9675 -2.6771 -7.4106 28.363
BT 504 CTRP2 -6.9592 -5.9577 -6.9594 26.7936
BT 232 CTRP2 -6.8189 -5.7679 -6.8192 25.8582
BT 179 CTRP2 -6.7839 -4.4974 -6.8346 25.8559
BT 482 CTRP2 -6.7827 -5.3373 -6.7865 25.6282
BT 224 CTRP2 -6.5435 -3.9021 -6.6582 24.469
BT 340 CTRP2 -6.4263 -4.8794 -6.4362 23.2707
BT 187 CTRP2 -6.3981 -4.5469 -6.4256 23.1421
BT 333 CTRP2 -6.3859 -2.4535 -6.8447 24.5774
BT 245 CTRP2 -6.2699 -5.3947 -6.2701 22.1948
BT 159 CTRP2 -5.9736 -4.7777 -5.9777 20.2309
BT 172 CTRP2 -5.9079 -3.4397 -6.0579 20.2956
BT 239 CTRP2 -5.8341 -5.1635 -5.8342 19.2869
BT147 CTRP2 -5.6338 -2.9272 -5.8839 18.8264
BT 320 CTRP2 -5.4674 -4.1169 -5.4873 16.907
BT 139 CTRP2 -5.1562 -4.6884 -5.1562 14.7638
BT 328 CTRP2 -4.4532 -3.1871 -4.5315 10.3431
BT 440 CTRP2 -4.1724 -0.0776 -5.4958 13.3745
BT 498 CTRP2 -3.2348 2.3693 -5.8464 12.7417
BT 444 CTRP2 0.5764 14.4894 -8.9291 16.9396
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 -5.7493 -4.5747 -5.7549 18.7842
Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Onda 10 GDSC1; GDSC2 -11.6998 -9.8543 -11.7011 60.6987
KNS-42 GDSC1; GDSC2 -11.3527 -7.7737 -11.4477 56.616
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 -11.2087 -8.628 -11.2291 55.6717
D-542MG GDSC1; GDSC2 -10.8587 -7.8881 -10.9146 52.2166
D-247MG GDSC1; GDSC2 -10.7308 -7.7775 -10.7905 50.9973
KINGS-1 GDSC1; GDSC2 -10.1812 -7.8229 -10.212 45.6199
D-336MG GDSC1; GDSC2 -9.8639 -7.9568 -9.8772 42.4043
GI-1 GDSC1; GDSC2 -9.8367 -7.5452 -9.8735 42.2205
D-263MG GDSC1; GDSC2 -9.7634 -8.8293 -9.7635 41.3405
KNS-81-FD GDSC1; GDSC2 -9.615 -7.5783 -9.6402 39.9635
D-392MG GDSC1; GDSC2 -9.2584 -6.8411 -9.3378 36.6433
Onda 11 GDSC1; GDSC2 -9.1809 -0.6799 -11.4586 41.8319
PFSK-1 GDSC2 -8.5474 -5.4091 -8.8796 30.7993
SNU-466 CTRP2 -8.4697 -7.5808 -8.4697 36.9589
MOG-G-CCM GDSC2 -8.4169 -6.6797 -8.4629 28.0613
8-MG-BA GDSC1; GDSC2; CTRP2 -8.1564 -7.4461 -8.1564 34.8634
DK-MG GDSC2; CTRP2 -8.1074 -7.0956 -8.1074 34.5359
SK-MG-1 GDSC2 -8.1052 -7.3541 -8.1057 24.7025
D283 Med GDSC1; GDSC2; CTRP2 -8.0636 -7.3457 -8.0636 34.2432
M059J GDSC2 -7.9852 -6.0999 -8.0905 24.0393
MOG-G-UVW GDSC2 -7.765 -6.385 -7.8064 21.4969
SW1783 GDSC2 -7.7555 -5.3919 -8.0218 22.602
D-245MG GDSC2 -7.6673 -5.5998 -7.8643 21.3439
SF539 GDSC1; GDSC2; CTRP2 -7.6541 -6.7537 -7.6541 31.4297
A-172 GDSC2; CTRP2 -7.6012 -6.173 -7.6022 31.1537
GB-1 GDSC1; GDSC2; CTRP2 -7.5373 -6.0678 -7.5387 30.7278
SF126 GDSC1; GDSC2; CTRP2 -7.4642 -6.7801 -7.4642 30.2341
SNU-626 CTRP2 -7.3099 -6.2044 -7.3101 29.2029
KNS-81 CTRP2 -7.2402 -5.6899 -7.2434 28.747
H4 GDSC2 -7.2031 -5.4307 -7.4082 16.7412
T98G GDSC2; CTRP2 -7.1903 -5.8625 -7.1914 28.406
D-566MG GDSC2 -7.1753 -5.9772 -7.2374 15.6884
YH-13 GDSC2; CTRP2 -7.1319 -6.047 -7.1321 28.0126
GOS-3 CTRP2 -7.0782 -4.8653 -7.1108 27.7624
CAS-1 GDSC1; GDSC2; CTRP2 -7.0313 -3.4671 -7.2734 32.389
SF268 GDSC1; GDSC2; CTRP2 -7.0034 -5.1698 -7.0162 27.1306
Daoy GDSC2; CTRP2 -6.883 -5.7496 -6.8835 26.3489
SW1088 GDSC2; CTRP2 -6.771 -4.877 -6.832 22.1719
YKG-1 GDSC2 -6.7603 4.1773 -11.5133 32.7386
TM-31 CTRP2 -6.7537 -5.3729 -6.7566 25.4921
D-502MG GDSC1; GDSC2 -6.6115 -1.2231 -8.7046 21.7691
D-423MG GDSC2 -6.605 -5.1182 -6.8718 11.1147
U-118MG GDSC2; CTRP2 -6.5888 -4.5685 -6.623 24.4952
LN-405 GDSC2 -6.5041 -5.0045 -6.8106 10.3418
SNU-1105 CTRP2 -6.4625 -5.7891 -6.4625 23.5352
KALS-1 GDSC1; GDSC2; CTRP2 -6.4272 -4.651 -6.4487 23.3714
Hs 683 GDSC2; CTRP2 -6.2951 -4.893 -6.3018 22.438
U-87MG ATCC GDSC1; GDSC2; CTRP2 -6.2643 -4.9457 -6.2691 22.2257
M059K CTRP2 -6.2362 -4.3714 -6.2706 22.138
GaMG GDSC2; CTRP2; CTRP1 -6.1496 -4.5065 -6.1496 51.0116
ONS-76 GDSC1; GDSC2; CTRP2 -6.0508 -4.0015 -6.1152 21.0009
U-251MG GDSC2; CTRP2 -6.0159 -3.8054 -6.1065 20.8084
LN-229 GDSC2; CTRP2; CTRP1 -5.9778 -4.2967 -6.0062 20.3894
GMS-10 CTRP2 -5.9478 -5.1657 -5.9479 20.0931
SF295 GDSC2; CTRP2; CTRP1 -5.9441 -2.7647 -5.9455 47.9345
SNU-489 CTRP2 -5.932 -3.7768 -6.021 20.2915
AM-38 GDSC1; GDSC2 -5.7505 -3.1548 -6.9783 8.7616
SNU-738 CTRP2 -5.46 -4.5512 -5.4618 16.8365
SNU-201 CTRP2 -5.4578 -4.3667 -5.464 16.8364
42-MG-BA GDSC2; CTRP2 -5.3891 -4.0516 -5.4106 16.39
Becker GDSC1; GDSC2; CTRP2 -5.2594 -1.2316 -6.0809 18.5287
KG-1-C CTRP2 -5.2016 -2.9862 -5.3963 15.7472
KNS-60 CTRP2 -5.0044 -3.6572 -5.0455 13.9233
CCF-STTG1 CTRP2 -4.9615 -3.0551 -5.1163 14.0371
LN-18 GDSC2; CTRP2 -4.8832 -4.1558 -4.8851 12.9794
SNB-75 GDSC1; GDSC2; CTRP2 -4.8071 -3.0702 -4.9441 12.9112
DBTRG-05MG GDSC2; CTRP2 -4.6835 -2.2461 -5.0699 13.0413
NMC-G1 GDSC1; GDSC2; CTRP2 -1.5466 4.8184 -5.7307 9.2471
⏷ Show the Full List of 68 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC1TKB GDSC1; GDSC2 -8.9805 -6.5618 -9.082 33.9779
ETK-1 GDSC1; GDSC2 -8.0647 -6.4101 -8.1228 24.5902
TGBC24TKB GDSC2 -4.1853 4.9555 -9.7825 19.6598
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2; CTRP1 -8.0939 -7.2947 -8.0939 34.4456
HEC-108 CTRP2; CTRP1 -7.6905 -7.1887 -7.6905 55.5414
JHUEM-1 CTRP2 -7.6113 -7.0568 -7.6113 31.2182
ESS-1 GDSC2; CTRP2 -7.5065 -6.7386 -7.5065 30.5169
MFE-319 GDSC2; CTRP2; CTRP1 -7.1549 -5.877 -7.1549 53.2078
MFE-280 GDSC2 -7.0757 -5.3667 -7.2901 15.5181
AN3-CA GDSC2; CTRP2 -6.8845 -5.3995 -6.8885 26.3706
KLE GDSC2; CTRP2; CTRP1 -6.8493 -3.9452 -6.8496 51.8759
HEC-1-B CTRP2 -6.8219 -4.9706 -6.8386 25.995
HEC-251 CTRP2; CTRP1 -6.624 -5.1981 -6.624 50.8951
HEC-151 CTRP2; CTRP1 -6.6219 -5.5079 -6.6227 26.3337
RL95-2 GDSC1; GDSC2; CTRP2 -6.4096 -5.2783 -6.4108 23.185
EFE-184 CTRP2 -6.3587 -4.7362 -6.4112 18.9654
JHUEM-3 CTRP2 -6.2026 -3.6905 -6.3277 22.2265
JHUEM-7 CTRP2 -6.1047 -4.1101 -6.1588 21.3258
EN GDSC2; CTRP2 -6.0768 -4.0621 -6.135 21.1531
HEC-50B CTRP2 -5.7055 -3.9931 -5.7493 18.6207
HEC-6 CTRP2; CTRP1 -5.4987 -3.8904 -5.4987 45.993
HEC-1-A CTRP2 -5.4899 -3.2297 -5.6499 17.5443
MFE-296 GDSC2; CTRP2 -5.4284 -3.3654 -5.5529 17.0089
HEC-265 CTRP2; CTRP1 -5.4134 -4.0266 -5.4134 45.6213
HEC-59 CTRP2; CTRP1 -1.8003 5.8952 -2.6708 31.7416
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 -6.176 -5.2936 -6.176 48.9432
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BB65-RCC GDSC1; GDSC2 -11.4079 -9.7388 -11.4087 57.8165
RXF 393L GDSC1; GDSC2 -10.5669 -9.226 -10.5673 49.404
TK-10 GDSC1; GDSC2 -10.4995 -8.8467 -10.5019 48.7305
LB2241-RCC GDSC1; GDSC2 -9.8647 -8.4903 -9.8662 42.3632
A-704 GDSC2 -9.8038 -8.1573 -9.8096 41.771
A-498 GDSC2 -9.2705 -6.7032 -9.3709 36.8567
HA7-RCC GDSC1; GDSC2 -8.8009 -5.329 -9.1801 33.4857
KTCTL-13 GDSC2 -8.612 -7.2169 -8.6237 29.8445
KTCTL-140 GDSC2 -8.455 -7.2257 -8.4623 28.2465
LB1047-RCC GDSC1; GDSC2 -8.3904 -6.1259 -8.5247 28.2481
LB996-RCC GDSC1; GDSC2 -8.046 -6.2507 -8.1282 24.5279
NCC010 GDSC2 -7.9889 -6.9211 -7.9967 23.572
KTCTL-1M GDSC2 -7.8632 -6.0239 -7.9737 22.8429
VMRC-RCW GDSC2; CTRP2; CTRP1 -7.8617 -5.8844 -7.8617 58.803
KMRC-3 CTRP2 -7.8255 -3.7324 -8.0786 33.3914
NCC021 GDSC2 -7.8129 -5.9423 -7.9366 22.4088
SW13 GDSC2 -7.7918 -5.9054 -7.9221 22.2322
BFTC-909 GDSC2 -7.668 -4.991 -8.0602 22.42
KTCTL-21 GDSC2 -7.5439 -5.1852 -7.8586 20.7555
786-O GDSC2; CTRP2 -7.5232 -6.0419 -7.5247 30.6338
CAL-54 GDSC2 -7.5216 16.9004 -18.5166 43.1734
KMRC-1 GDSC2; CTRP2 -7.1772 -5.925 -7.1779 28.317
KTCTL-26A GDSC2 -7.0904 -5.673 -7.2146 15.1692
SW156 GDSC2 -6.8482 -4.8167 -7.2496 14.3164
KMRC-2 CTRP2 -6.7013 -5.1996 -6.7068 25.1506
VMRC-RCZ GDSC2; CTRP2 -6.676 -4.2976 -6.7428 25.1896
KTCTL-195 GDSC2 -6.6001 -5.6512 -6.6855 10.0455
TUHR4TKB CTRP2 -6.458 -5.3437 -6.459 23.5085
OS-RC-2 GDSC1; GDSC2; CTRP2 -6.3481 -4.2706 -6.3984 22.9403
KMRC-20 GDSC2; CTRP2 -5.7873 -4.3801 -5.8022 19.0693
UO-31 GDSC2; CTRP2 -5.6584 -3.7285 -5.7348 18.3747
SN12C GDSC2 -5.5718 1.2939 -9.0529 20.1373
769-P GDSC2; CTRP2 -5.4701 -1.7012 -6.1174 19.2576
ACHN GDSC2; CTRP2 -4.8725 -1.0808 -5.7408 16.1604
Caki-1 GDSC2; CTRP2 -4.7361 -0.5406 -5.8394 16.1914
TUHR10TKB CTRP2 -4.4115 -2.4115 -4.7169 23.2329
TUHR14TKB CTRP2 -4.1796 2.6884 -6.8459 18.7301
RCC10RGB GDSC1; GDSC2; CTRP2; CTRP1 -2.7179 3.4319 -5.9451 12.1253
Caki-2 CTRP2 -2.249 4.4601 -6.0835 11.843
SNU-1272 CTRP2 -1.7046 2.6528 -4.7885 5.6837
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 63 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC2998 GDSC1; GDSC2 -10.7982 -9.3354 -10.7988 51.7223
SW480 CTRP1 -10.071 5.7757 -14.084 62.0936
NCI-H747 GDSC1; GDSC2; CTRP2 -8.4504 -3.4406 -8.8253 37.8082
SK-CO-1 GDSC2; CTRP2; CTRP1 -8.2976 -7.337 -8.2976 58.1858
DiFi GDSC2 -8.2937 -6.4898 -8.3563 26.9104
CL-11 GDSC1; GDSC2; CTRP2 -8.0114 -6.0557 -8.0174 33.9139
SW626 GDSC2 -7.9098 -5.4507 -8.1721 24.1208
LS513 GDSC1; CTRP2; CTRP1 -7.7625 -4.744 -7.7627 55.8516
SW620 GDSC2; CTRP2; CTRP1 -7.7445 -5.7973 -7.7523 34.3944
SNU-C2A CTRP2; CTRP1 -7.7046 -5.071 -7.7047 55.6018
CaR-1 GDSC2 -7.6014 -6.3485 -7.6371 19.8262
C2BBe1 GDSC1; GDSC2; CTRP2; CTRP1 -7.4755 -5.1794 -7.4755 54.6045
CL-34 CTRP1 -7.4377 -5.9887 -7.4391 64.0054
CCK-81 GDSC2; CTRP2 -7.3882 -5.3635 -7.4029 29.7753
NCI-H508 GDSC2; CTRP2; CTRP1 -7.3242 -5.9578 -7.3253 29.3017
GP5d GDSC2 -7.2586 -5.1063 -7.5774 17.9313
HCC-56 CTRP2 -7.1855 -5.769 -7.1873 28.3765
SNU-407 GDSC2; CTRP2 -7.161 -5.1603 -7.2114 25.1314
LoVo GDSC2; CTRP2; CTRP1 -7.102 -5.3513 -7.1106 29.7985
SNU-283 GDSC2 -7.0859 -5.0618 -7.4076 16.2244
RKO GDSC1; GDSC2; CTRP2; CTRP1 -7.0819 -6.2036 -7.0819 27.6773
SNU-C2B GDSC2 -7.0484 -4.6292 -7.537 16.8113
SW48 GDSC2; CTRP2; CTRP1 -7.0391 -6.0074 -7.0391 52.7036
SW837 GDSC2 -6.956 -4.7775 -7.3793 15.5149
SW1463 GDSC2; CTRP2 -6.9533 -5.1374 -6.9661 26.8602
COLO 320HSR GDSC1; GDSC2 -6.8395 -4.4363 -7.4006 15.167
HCT 116 GDSC2; CTRP2; CTRP1 -6.735 -5.8974 -6.7351 25.3579
SNU-C1 GDSC1; GDSC2; CTRP2 -6.6444 -4.5333 -6.6843 24.8862
HT-55 GDSC2; CTRP2; CTRP1 -6.6373 -5.7881 -6.6374 26.4414
LS123 GDSC1; GDSC2; CTRP2; CTRP1 -6.6204 -4.2279 -6.6923 26.5811
SW948 GDSC2; CTRP2; CTRP1 -6.6022 -5.4148 -6.6034 24.4732
MDST8 GDSC1; GDSC2; CTRP2; CTRP1 -6.598 -5.1282 -6.6037 26.1803
T84 GDSC2; CTRP2 -6.5973 -4.9855 -6.6073 24.4118
NCI-H716 GDSC1; GDSC2; CTRP2 -6.589 -4.5306 -6.6265 24.5076
DLD-1 CTRP2; CTRP1 -6.545 -5.5438 -6.545 50.5508
SNU-C4 CTRP2; CTRP1 -6.3783 -5.6752 -6.3783 22.9171
RCM-1 [Human ESC] GDSC2; CTRP2; CTRP1 -6.3591 -3.4617 -6.5434 23.4799
SNU-81 GDSC2; CTRP2; CTRP1 -6.314 -4.6061 -6.3341 22.6095
SNU-175 GDSC2; CTRP1 -6.2993 -5.1431 -6.3011 26.5037
HCT 15 GDSC2; CTRP2 -6.2579 -4.7383 -6.2693 22.2051
SNU-1033 CTRP2 -6.2397 -3.6527 -6.3749 22.4563
SW1417 GDSC2; CTRP2 -6.2012 -1.7149 -6.8963 24.2644
HT-29 GDSC2; CTRP2; CTRP1 -6.1546 -5.5187 -6.1546 21.4757
LS180 GDSC2; CTRP2; CTRP1 -6.1187 -4.4459 -6.1419 21.314
SW403 CTRP1 -6.1059 1.0972 -6.3165 89.9408
HT115 GDSC2; CTRP2; CTRP1 -6.0191 -5.3506 -6.0191 20.5695
LS411N GDSC1; GDSC2; CTRP2; CTRP1 -5.9104 -2.7832 -5.9117 47.7877
LS1034 GDSC1; GDSC2; CTRP2 -5.7992 -2.4499 -6.2075 20.5519
SW1116 GDSC2 -5.6983 -2.6033 -7.2098 10.0616
SNU-503 CTRP2 -5.6132 -3.3846 -5.7495 18.3263
COLO201 CTRP2 -5.3088 -2.6516 -5.61 16.8889
CL-40 CTRP1 -5.2446 -3.7285 -5.2921 33.2077
OUMS-23 CTRP2 -5.1533 -3.6533 -5.2049 14.9551
HCT 8 CTRP2; CTRP1 -5.139 -4.0961 -5.1482 14.6795
KM12 GDSC1; GDSC2; CTRP2; CTRP1 -5.094 -3.3583 -5.1915 14.7188
SNU-C5 GDSC2; CTRP2; CTRP1 -4.9637 -3.0557 -5.1186 15.0401
GP2d CTRP2; CTRP1 -4.9208 -2.1375 -4.9218 43.4773
SNU-61 GDSC2; CTRP2; CTRP1 -4.7868 -3.2884 -4.8726 13.5119
COLO 320 CTRP2; CTRP1 -4.7649 -1.9999 -5.25 13.9256
COLO205 GDSC2; CTRP2; CTRP1 -4.6433 0.4988 -4.7163 42.3914
SNU-1040 CTRP1 -4.4202 -2.7952 -4.5979 22.4363
CW-2 GDSC1; GDSC2; CTRP2; CTRP1 -4.3973 -0.8985 -5.3356 13.3143
COLO 678 GDSC2; CTRP2; CTRP1 -2.4748 4.4987 -6.2815 13.039
⏷ Show the Full List of 63 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 -7.9186 -6.4551 -7.961 23.0434
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HLE GDSC2 -7.5779 -5.6131 -7.763 20.384
JHH-1 GDSC2; CTRP2 -7.5179 -6.2851 -7.5182 30.5941
PLC/PRF/5 CTRP2 -7.4427 -5.0253 -7.479 30.2122
SNU-423 GDSC2; CTRP2 -7.1643 -5.3962 -7.1727 28.2568
JHH-4 GDSC2; CTRP2 -7.1337 -5.6568 -7.1364 28.033
JHH-2 GDSC2; CTRP2 -6.9995 -5.1758 -7.0119 27.168
HuH-6 CTRP2 -6.6783 -3.9576 -6.9203 24.0058
SK-HEP-1 GDSC2; CTRP2 -6.5979 -4.9744 -6.6083 24.4756
HLF CTRP2 -6.5436 -5.2031 -6.5469 24.0884
SNU-387 GDSC2; CTRP2 -6.4982 -4.0079 -6.5926 24.0956
JHH-7 GDSC2 -6.4485 -4.9729 -6.7656 9.852
SNU-182 CTRP2 -6.1343 -2.8434 -6.4535 22.4602
Hep 3B2.1-7 GDSC2; CTRP2 -6.0782 -3.4114 -6.2491 21.556
JHH-5 CTRP2 -6.0039 -3.8701 -6.0837 20.7403
Hep-G2/C3A GDSC2 -5.9125 -4.2397 -6.5807 6.7615
Li-7 CTRP2 -5.8075 -2.7534 -6.123 20.2678
SNU-878 CTRP2 -5.7742 -4.7868 -5.7759 18.9376
Huh-7 GDSC2 -5.6974 -2.7877 -7.1168 9.475
SNU-475 CTRP2 -5.6107 -4.3066 -5.6238 17.8822
SNU-449 GDSC2; CTRP2; CTRP1 -5.5144 -2.7972 -5.5149 46.0622
SNU-886 CTRP2 -5.4403 -4.182 -5.4547 16.7472
HuH-1 GDSC2; CTRP2 -5.2681 14.5065 -13.6741 36.7644
Hep-G2 CTRP2; CTRP1 -5.1497 -3.7309 -5.1907 15.9418
SNU-761 CTRP2 -5.092 -3.0252 -5.2664 14.9794
JHH-6 GDSC2; CTRP2; CTRP1 -4.6379 -3.1036 -4.6379 42.2429
SNU-398 GDSC2; CTRP1 -4.5448 -0.7712 -5.542 17.1223
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 226 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LXF 289 GDSC1; GDSC2; CTRP2; CTRP1 -10.8187 -8.3832 -10.8187 72.2403
LC-2/ad GDSC1; GDSC2 -9.5248 -8.41 -9.5253 38.9484
COR-L51 CTRP1 -8.941 -3.7652 -9.2841 71.2978
NCI-H847 GDSC1; GDSC2 -8.851 -8.0386 -8.8511 32.1843
NCI-H1975 GDSC1; GDSC2; CTRP2; CTRP1 -8.7815 -7.7312 -8.7815 60.2939
ABC-1 GDSC2 -8.5902 -7.3124 -8.5975 29.6036
NCI-H748 GDSC1; GDSC2 -8.2895 -7.0115 -8.3016 26.6102
IST-SL1 GDSC1; GDSC2 -8.1315 -6.7919 -8.1517 25.0658
Lu-139 GDSC1 -8.1019 -6.9434 -8.1117 30.7867
NCI-H69 GDSC1; GDSC2; CTRP2 -8.0992 -6.4551 -8.1007 34.4858
SBC-1 GDSC1; GDSC2 -8.0817 -6.8272 -8.0975 24.544
NCI-H2804 GDSC2 -8.0517 -6.0861 -8.1654 24.7498
NCI-H290 GDSC2 -8.0483 -6.7105 -8.0714 24.2457
NCI-H1693 GDSC2 -8.035 -6.0674 -8.1512 24.5952
HCC33 GDSC1; GDSC2; CTRP1 -8.0324 -6.9037 -8.0324 63.3413
NCI-H2141 GDSC1; GDSC2; CTRP2; CTRP1 -8.005 -6.8833 -8.0051 33.8514
NCI-H1869 GDSC1; GDSC2; CTRP2 -7.9916 -6.1586 -7.9955 33.7743
SHP-77 GDSC1; GDSC2; CTRP2; CTRP1 -7.9774 -6.2124 -7.9774 56.7911
NCI-H446 GDSC1; GDSC2; CTRP2 -7.9683 -6.9068 -7.9684 33.606
NCI-H2818 GDSC2 -7.888 -6.6728 -7.9068 22.6157
NCI-H2810 GDSC2 -7.8562 -6.2951 -7.9167 22.5114
EMC-BAC-1 GDSC2 -7.8398 -6.37 -7.8882 22.284
NCI-H2795 GDSC2 -7.7931 -6.3678 -7.8387 21.8003
NCI-H82 GDSC1; GDSC2; CTRP1 -7.7865 -6.5264 -7.7865 62.1516
NCI-H522 GDSC2; CTRP2; CTRP1 -7.7125 -6.2329 -7.7125 55.6369
NCI-H2731 GDSC2 -7.6964 -6.5335 -7.7179 20.7065
NCI-H2373 GDSC2 -7.6497 -6.2074 -7.7088 20.4321
HCC827 GDSC2; CTRP2; CTRP1 -7.595 -6.6497 -7.595 31.1088
NCI-H2869 GDSC2 -7.5764 -5.431 -7.8147 20.6592
COR-L303 GDSC2 -7.5337 -6.4651 -7.5533 19.0644
HOP-62 GDSC1; GDSC2; CTRP2 -7.4976 -5.6739 -7.5045 30.4083
DMS 273 GDSC2; CTRP2; CTRP1 -7.4943 -5.6239 -7.4943 54.6864
RERF-LC-A1 CTRP2 -7.4664 -6.9165 -7.4664 30.2489
NCI-H1915 GDSC2; CTRP2; CTRP1 -7.461 -6.0824 -7.461 54.5413
LC-1/sq GDSC2 -7.4539 -5.6845 -7.6083 18.9756
NCI-H1963 GDSC1; GDSC2; CTRP1 -7.4205 -5.7793 -7.4242 35.3632
EBC-1 GDSC2; CTRP2; CTRP1 -7.4181 -5.2185 -7.4181 56.7839
NCI-H1703 GDSC2; CTRP2 -7.3973 -6.1153 -7.3978 29.7886
NCI-H250 GDSC2 -7.3973 -5.7241 -7.5361 18.3238
COLO 699 CTRP2; CTRP1 -7.3934 -5.4908 -7.4035 29.7944
SCLC-21H CTRP1 -7.3601 -6.3274 -7.3602 63.0682
NCI-H2081 GDSC1; GDSC2; CTRP2; CTRP1 -7.3571 -5.5588 -7.3645 29.5427
NCI-H146 GDSC2 -7.3551 -5.7572 -7.4817 17.8354
PaCa-3 GDSC2 -7.3503 -5.5385 -7.536 18.1083
A-427 GDSC2 -7.3313 -5.6708 -7.4782 17.7063
SBC-3 GDSC2 -7.2991 -5.4513 -7.5063 17.7136
COR-L321 GDSC2 -7.2756 -5.7582 -7.3947 16.9981
EMC-BAC-2 GDSC2 -7.2602 -5.438 -7.468 17.3277
NCI-H2227 GDSC1; GDSC2 -7.2571 -5.9002 -7.3417 16.6281
NCI-H1734 GDSC2; CTRP2 -7.2487 -5.3675 -7.2598 28.8301
NCI-H1648 GDSC1; GDSC2 -7.2235 -5.8817 -7.3091 16.2964
LB647-SCLC GDSC1; GDSC2 -7.203 -5.2407 -7.4703 17.0866
RERF-LC-Sq1 GDSC2 -7.1904 -5.1052 -7.5043 17.2232
NCI-H1930 CTRP1 -7.1846 -6.425 -7.1846 89.9135
Calu-3 GDSC2; CTRP2; CTRP1 -7.1445 -5.3939 -7.1445 53.1625
DV-90 CTRP2; CTRP1 -7.1262 -5.5327 -7.1262 53.083
LC-1/sq-SF CTRP2; CTRP1 -7.0902 -4.9879 -7.0902 52.9262
Lu-134-A GDSC1; GDSC2 -7.087 -5.2628 -7.3372 15.8312
NCI-H2722 GDSC2 -7.0752 -5.5231 -7.2405 15.2419
NCI-H1105 GDSC2; CTRP2; CTRP1 -7.0423 -5.6219 -7.0445 27.4201
NCI-H2369 GDSC2 -7.0286 -5.7076 -7.1381 14.4705
NCI-H1092 GDSC1; GDSC2; CTRP2 -7.0134 -3.3285 -7.2862 28.1519
NCI-H23 GDSC1; GDSC2; CTRP2; CTRP1 -6.9908 -5.456 -6.9908 52.4931
HCC4006 CTRP2; CTRP1 -6.9476 -4.4039 -7.0183 27.0187
NCI-H1650 GDSC1; GDSC2; CTRP2 -6.9381 -4.4121 -7.0072 26.9499
NCI-H1341 GDSC2; CTRP2 -6.9197 -5.7316 -6.9204 26.5951
NCI-H1437 GDSC2; CTRP1 -6.9074 -5.4098 -6.9074 57.8984
NCI-H810 GDSC2; CTRP2; CTRP1 -6.8544 -5.3023 -6.8544 51.8988
COR-L95 GDSC1; CTRP2 -6.852 -4.7801 -6.8814 26.2389
NCI-H1694 GDSC1; GDSC2; CTRP2; CTRP1 -6.8502 -5.7106 -6.8507 26.0675
NCI-H520 GDSC2; CTRP2 -6.8413 -4.7955 -6.8692 26.1625
COR-L23 GDSC2; CTRP1 -6.8362 -5.5148 -6.8381 30.7428
COR-L311 GDSC2 -6.7874 -5.2606 -7.0141 12.7058
NCI-H2591 GDSC2 -6.7834 -4.717 -7.2228 13.8946
NCI-H524 GDSC1; GDSC2 -6.7818 -4.6267 -7.2591 14.1016
NCI-H720 GDSC1; GDSC2 -6.7759 -5.5568 -6.9041 12.0401
NCI-H345 GDSC1; GDSC2 -6.7458 -5.2574 -6.9704 12.2784
CPC-N GDSC1; GDSC2 -6.7295 -4.8952 -7.0926 12.9129
NCI-H1304 GDSC1 -6.6971 -5.7114 -6.7756 13.6775
NCI-H1155 GDSC1; GDSC2; CTRP2 -6.6932 -5.5298 -6.6941 25.0811
LCLC-97TM1 GDSC2; CTRP2; CTRP1 -6.6905 -5.0852 -6.6905 51.185
NCI-H526 GDSC1; GDSC2; CTRP2 -6.6743 -5.3389 -6.6769 24.96
NCI-H1581 GDSC1; GDSC2; CTRP2 -6.6717 -4.4182 -6.7244 25.1126
NCI-H2803 GDSC2 -6.6581 -5.3019 -6.8599 11.2732
NCI-H513 GDSC2 -6.6568 -3.5491 -7.621 15.7864
Calu-6 GDSC1; GDSC2; CTRP2; CTRP1 -6.6354 -5.4616 -6.6354 53.2222
COR-L105 GDSC2; CTRP2 -6.6348 -4.3031 -6.6984 24.9031
Lu-135 GDSC2 -6.6243 -5.1451 -6.8819 11.2542
HCC1588 CTRP2 -6.6224 -5.2831 -6.6253 24.6142
HCC78 GDSC2; CTRP2; CTRP1 -6.6009 -5.6486 -6.6009 50.7946
NCI-H64 GDSC1; GDSC2 -6.5893 -4.3948 -7.163 12.773
SK-LU-1 GDSC2; CTRP2; CTRP1 -6.5889 -5.2717 -6.5916 26.1043
NCI-H358 GDSC2; CTRP2; CTRP1 -6.5828 -4.5564 -6.5828 50.7156
NCI-H1876 GDSC1; GDSC2; CTRP1 -6.5774 -4.469 -6.6199 28.8613
NCI-H2087 GDSC2; CTRP2 -6.5713 -4.1063 -6.6564 24.5524
NCI-H2170 GDSC2; CTRP2 -6.5208 -5.0954 -6.5261 23.9427
IST-SL2 GDSC1; GDSC2 -6.4707 -2.2302 -8.0807 17.8442
T3M-10 CTRP2; CTRP1 -6.4446 -3.8039 -6.5685 23.8398
NCI-H209 GDSC1; GDSC2 -6.4325 -5.2034 -6.6549 9.1402
HCC2935 CTRP2; CTRP1 -6.3829 -2.6368 -6.7851 24.3556
EPLC-272H GDSC2; CTRP2; CTRP1 -6.3333 -3.0644 -6.3347 49.629
NCI-H510A GDSC1; GDSC2 -6.3294 -3.8393 -7.166 11.8316
NCI-H740 GDSC2 -6.3109 -1.9721 -8.0615 17.1859
NCI-H2461 GDSC2 -6.3024 -2.7034 -7.6934 14.9715
RERF-LC-MS GDSC2; CTRP2 -6.2947 -3.7131 -6.423 22.8531
SW1271 GDSC2; CTRP2 -6.2854 -4.2647 -6.3327 22.511
SBC-5 GDSC2; CTRP2 -6.284 -5.2361 -6.2849 22.3441
LK2 CTRP2 -6.2779 -3.7333 -6.4012 22.7233
NCI-H1836 GDSC1; GDSC2; CTRP1 -6.2682 -3.7726 -6.3838 26.7163
NCI-H2029 GDSC2; CTRP2; CTRP1 -6.1947 -4.9127 -6.1947 49.0251
NCI-H1048 GDSC2; CTRP1 -6.1923 -5.2633 -6.1923 54.4381
UMC-11 GDSC2 -6.1856 7.3061 -12.5757 33.4625
COR-L32 GDSC2 -6.179 -4.6841 -6.6196 7.9325
HOP-92 GDSC2; CTRP2 -6.163 -3.6872 -6.2854 21.9001
NCI-H1355 GDSC1; GDSC2; CTRP2; CTRP1 -6.1235 -4.4177 -6.1235 48.7149
HCC2279 CTRP2 -6.1198 -5.0855 -6.121 21.2471
COR-L279 GDSC2; CTRP1 -6.1076 -4.5814 -6.1076 54.0284
NCI-H1755 GDSC2; CTRP2; CTRP1 -6.1068 -4.2439 -6.1465 22.7873
NCI-H841 GDSC2; CTRP2; CTRP1 -6.1023 -3.7037 -6.217 21.5197
NCI-H889 CTRP2 -6.1001 -4.7919 -6.106 21.1309
PC-14 GDSC2; CTRP2 -6.0744 -4.6179 -6.0861 20.9786
Sq-1 CTRP2; CTRP1 -6.0299 -4.9188 -6.0321 22.1012
NCI-H2291 GDSC2; CTRP2 -6.0213 -3.0808 -6.2659 21.4383
HCC366 GDSC2; CTRP2 -6.0172 -4.62 -6.0272 20.5903
NCI-H2347 GDSC2 -6.0149 -0.6238 -8.4694 18.5099
HCC1359 CTRP1 -5.9896 -4.0982 -6.0382 43.7446
HCC95 CTRP2 -5.9879 -5.0179 -5.9888 20.3638
LCLC-103H GDSC2; CTRP2; CTRP1 -5.9801 -5.3847 -5.9801 48.0899
RERF-LC-KJ GDSC2; CTRP1 -5.968 -4.7391 -5.968 53.3532
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2; CTRP1 -5.9652 -4.5313 -5.9652 48.0252
NCI-H596 GDSC2; CTRP1 -5.9642 -4.1774 -6.0029 24.0053
COLO 668 GDSC1; GDSC2; CTRP2; CTRP1 -5.954 -4.0218 -5.954 47.9764
NCI-H2228 GDSC2; CTRP2 -5.9403 -1.166 -6.8265 23.2468
HCC1438 CTRP2 -5.9224 -5.006 -5.9231 19.878
NCI-H1436 GDSC1; GDSC2 -5.8525 -4.3141 -6.4897 5.9949
NCI-H1688 GDSC2 -5.8525 -4.0172 -6.637 6.9222
NCI-H292 GDSC2; CTRP2 -5.8494 -4.8655 -5.8508 19.4396
IA-LM GDSC2; CTRP2 -5.8318 -3.1988 -6.0297 20.0055
NCI-H2171 GDSC1; GDSC2 -5.8228 -2.1757 -7.5293 12.4223
NCI-H2106 CTRP2 -5.7988 -4.0063 -5.8466 19.2586
Calu-1 CTRP2 -5.7866 -4.4379 -5.7984 19.0089
LK-2 GDSC2 -5.767 -2.8326 -7.1534 9.9133
HCC44 GDSC2; CTRP2; CTRP1 -5.7657 -3.877 -5.7658 47.1562
Lu-99 CTRP2; CTRP1 -5.7395 -3.9649 -5.7395 47.042
NCI-H838 GDSC2; CTRP2 -5.7287 -4.829 -5.7297 18.6309
NCI-H1299 GDSC1; GDSC2; CTRP2; CTRP1 -5.7076 -3.7161 -5.7076 46.9028
HCC15 GDSC2; CTRP2; CTRP1 -5.7064 -4.0553 -5.7435 18.6037
NCI-H647 GDSC2; CTRP2 -5.6974 -2.8862 -5.9647 19.3581
NCI-H2085 GDSC2; CTRP2 -5.6335 -3.2818 -5.7942 18.5482
NCI-H650 GDSC2; CTRP2; CTRP1 -5.6205 -3.208 -5.6207 46.5238
NCI-H2135 GDSC1; GDSC2 -5.6134 -3.39 -6.7455 6.8867
DMS 114 GDSC1; GDSC2; CTRP2 -5.6126 -3.3581 -5.7545 18.2981
COR-L88 GDSC1; GDSC2; CTRP1 -5.6118 -1.2804 -5.6293 51.6122
NCI-H1651 GDSC2; CTRP2 -5.5636 -2.2984 -6.0018 19.0484
DMS 53 GDSC2; CTRP2 -5.5597 -3.0295 -5.7756 18.2097
NCI-H2196 GDSC1; GDSC2; CTRP2 -5.5555 -2.4995 -5.9266 18.7912
NCI-H1339 CTRP2 -5.5458 -4.7447 -5.5464 17.4063
DMS 79 GDSC1; GDSC2 -5.5403 0.7345 -8.7471 18.518
NCI-H322M GDSC1; GDSC2 -5.5377 1.8039 -9.2796 21.1062
NCI-H187 GDSC1 -5.5159 -0.6452 -8.0374 17.719
NCI-H1568 GDSC2; CTRP2; CTRP1 -5.5145 -3.3648 -5.5145 46.0618
DMS 454 CTRP2 -5.4957 0.091 -6.8938 22.1989
NCI-H226 GDSC1; GDSC2; CTRP2 -5.495 -4.4855 -5.4985 17.0763
KNS-62 GDSC2; CTRP2; CTRP1 -5.4654 -3.7901 -5.4654 45.7765
ChaGo-K-1 GDSC2; CTRP2; CTRP1 -5.4591 -3.0125 -5.4593 45.8206
NCI-H3255 GDSC2; CTRP1 -5.4504 -1.6938 -6.0992 22.5612
NCI-H1993 GDSC2 -5.3931 0.2278 -8.3734 16.0975
Lu-65 GDSC1; GDSC2; CTRP2; CTRP1 -5.3792 -2.7946 -5.3795 45.4729
Ms-1 GDSC1; GDSC2 -5.3309 0.9685 -8.693 17.6276
NCI-H661 GDSC2; CTRP2; CTRP1 -5.3293 -3.3707 -5.3293 45.2548
NCI-H2405 GDSC2; CTRP2; CTRP1 -5.2785 -2.4534 -5.2794 45.0353
NCI-H1373 CTRP2; CTRP1 -5.2665 -3.4459 -5.2665 44.9812
MOR/CPR CTRP2 -5.2588 -4.4327 -5.2604 15.4905
NCI-H196 GDSC2; CTRP2 -5.2552 -3.1534 -5.4123 16.0078
NCI-H727 GDSC2; CTRP2; CTRP1 -5.2405 -2.7872 -5.2407 44.8683
SW1573 GDSC2 -5.2229 -1.514 -7.3693 9.7247
SK-MES-1 GDSC2; CTRP2 -5.2144 -2.6311 -5.5136 16.2518
NCI-H3122 GDSC2 -5.1763 -0.3946 -7.8898 12.7375
NCI-H2444 GDSC2; CTRP2 -5.1428 -4.742 -5.1428 14.7094
NCI-H211 GDSC1; GDSC2; CTRP2 -5.1278 -3.5748 -5.1893 14.8191
NCI-H1623 GDSC2; CTRP2 -5.1113 -1.5401 -5.7992 17.0364
NCI-H1770 GDSC1; GDSC2 -5.0831 -2.6369 -6.7095 5.2804
NCI-H1792 GDSC2; CTRP2; CTRP1 -4.9669 -3.3486 -4.9669 43.6762
NCI-H2122 GDSC2; CTRP2; CTRP1 -4.948 -3.0141 -5.1122 13.9808
LOU-NH91 GDSC2; CTRP2 -4.9008 -2.5475 -5.1995 14.1587
NCI-H835 GDSC2 -4.8722 4.7783 -10.2266 23.1813
NCI-H1184 CTRP2 -4.8561 -2.8421 -5.354 9.3675
NCI-H2342 GDSC2; CTRP2; CTRP1 -4.7788 -1.7946 -5.3455 14.3656
NCI-H1781 GDSC2; CTRP1 -4.7453 -2.8656 -4.9316 15.002
NCI-H1838 GDSC1; GDSC2; CTRP2 -4.6711 -2.8764 -4.8475 12.1761
HCC1195 CTRP2; CTRP1 -4.6164 -3.5428 -4.6472 11.2933
HCC2108 CTRP2; CTRP1 -4.61 -2.8403 -4.7914 11.7864
LUDLU-1 CTRP2 -4.5734 0.3446 -6.086 16.759
NCI-H1573 GDSC2; CTRP2; CTRP1 -4.545 -2.5186 -4.545 41.8382
NCI-H441 GDSC2; CTRP2; CTRP1 -4.5053 -2.0907 -4.9383 12.0351
NCI-H2030 GDSC2; CTRP2; CTRP1 -4.4208 -1.6102 -5.0459 12.2232
NCI-H2286 CTRP2; CTRP1 -4.4074 -2.4514 -4.4074 41.2387
HCC1833 CTRP2; CTRP1 -4.3749 0.3793 -5.9091 15.567
VMRC-LCD GDSC2; CTRP2; CTRP1 -4.3236 -1.7229 -4.3245 40.8755
NCI-H1666 GDSC1; GDSC2; CTRP2; CTRP1 -4.2478 0.9126 -4.3354 40.7056
NCI-H2110 GDSC2; CTRP2; CTRP1 -4.1529 -0.412 -5.3184 12.637
NCI-H2009 GDSC2; CTRP2; CTRP1 -4.1362 -0.0374 -4.163 40.1107
NCI-H1435 GDSC2; CTRP2; CTRP1 -4.0181 -1.0081 -4.0218 41.3185
NCI-H1395 CTRP2 -3.9732 -0.6918 -5.0111 10.9479
NCI-H1944 GDSC2; CTRP2; CTRP1 -3.8291 1.478 -3.948 38.9506
A-549 GDSC2; CTRP2; CTRP1 -3.7573 -1.8186 -3.7574 38.4069
CAL-12T GDSC2; CTRP2; CTRP1 -3.7098 -1.7339 -4.2644 7.2617
EKVX GDSC1; GDSC2; CTRP2 -3.6516 1.2244 -5.6434 12.7895
NCI-H2073 CTRP1 -3.6383 -2.047 -4.0502 13.2802
NCI-H460 GDSC2; CTRP2; CTRP1 -3.5325 -2.146 -3.8985 5.3387
RERF-LC-Ad2 CTRP2 -3.5183 0.576 -5.2026 10.7027
Lu-165 GDSC1; GDSC2 -3.3472 3.9444 -8.6853 12.6974
NCI-H2172 GDSC2; CTRP2; CTRP1 -3.2388 -1.5676 -3.8907 4.609
NCI-H2023 GDSC2; CTRP2; CTRP1 -3.2319 0.541 -4.9316 9.5915
NCI-H322 CTRP2 -2.7482 -0.8126 -3.8508 3.467
HCC1171 CTRP2 -2.2347 4.6964 -6.19 12.2395
NCI-H128 GDSC1 -1.7615 8.0716 -9.5989 15.8157
NCI-H2126 CTRP2; CTRP1 -1.6892 0.3476 -1.6905 30.7145
NCI-H1793 GDSC2; CTRP2; CTRP1 -0.9855 4.8192 -1.4736 27.3826
BEN GDSC2; CTRP2; CTRP1 -0.9192 1.768 -0.9375 26.0827
Lu-99A GDSC2 -0.511 3.8688 -7.1 1.4578
NCI-H1563 GDSC2; CTRP2 -0.4923 6.4733 -5.7991 7.9407
RERF-LC-Ad1 CTRP2 -0.0069 9.6576 -6.9965 11.6805
NCI-H2595 GDSC2 0.063 4.5593 -7.1243 1.2159
NCI-H2066 GDSC2 0.2125 3.0749 -6.5541 0.145
Hs 888.Lu CTRP2 -3.3066 0.9887 -5.2197 10.3252
⏷ Show the Full List of 226 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 -8.5894 -7.3967 -8.5941 29.5823
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 -7.3106 -6.8731 -7.3106 29.2073
SYO-1 CTRP2 -6.2175 -5.4856 -6.2176 21.8447
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 -7.0025 -5.5969 -7.0048 27.0897
JHOS-4 GDSC2; CTRP1 -9.2307 -7.5642 -9.2307 69.1386
OVCAR-4 GDSC1; GDSC2; CTRP2; CTRP1 -8.6061 -6.8907 -8.6072 37.8747
ES-2 GDSC1; GDSC2 -8.4507 -7.1055 -8.4631 28.2294
RMUG-S CTRP1 -8.3902 -6.7677 -8.3911 76.6024
TOV-21G GDSC2; CTRP2 -8.2107 -6.9745 -8.2108 35.227
Caov-4 GDSC2 -8.082 -6.4136 -8.1409 24.7678
OVK18 GDSC2; CTRP2; CTRP1 -7.9833 -6.3479 -7.985 36.0818
A2780 GDSC2; CTRP2; CTRP1 -7.8352 -6.6822 -7.8353 32.7155
JHOC-5 CTRP2; CTRP1 -7.7851 -6.1522 -7.7873 32.3877
COV644 CTRP2; CTRP1 -7.6422 -6.5252 -7.6423 31.4248
JHOM-1 CTRP2; CTRP1 -7.5765 -6.2287 -7.5771 30.9873
OVCAR-3 GDSC2 -7.367 -5.5972 -7.5373 18.1909
ONCO-DG-1 CTRP2 -7.3589 -5.5649 -7.3662 29.5547
MCAS CTRP2 -7.341 -5.5494 -7.3484 29.4352
TYK-nu GDSC2; CTRP2; CTRP1 -7.3261 -5.3356 -7.3404 31.4227
OV-90 GDSC2; CTRP2; CTRP1 -7.2807 -6.0255 -7.2812 29.0088
OV7 CTRP2; CTRP1 -7.2304 -5.9568 -7.2311 28.6728
OV56 GDSC2; CTRP2 -7.1251 -6.0312 -7.1253 27.9671
OC 314 GDSC2; CTRP2 -7.0589 -6.1867 -7.0589 27.458
SNU-840 CTRP2; CTRP1 -7.0577 -5.1838 -7.0713 29.4989
OVKATE GDSC2; CTRP1 -7.0516 -5.9409 -7.0519 32.4375
SNU-8 CTRP2 -6.9151 -5.9885 -6.9151 26.562
OVCAR-8 GDSC2; CTRP2; CTRP1 -6.8861 -5.6509 -6.8871 26.3712
COV318 CTRP1 -6.777 -5.5497 -6.777 86.7994
Caov-3 GDSC2; CTRP2; CTRP1 -6.6627 -5.8807 -6.6627 26.6227
OAW28 GDSC2; CTRP2 -6.6411 -4.8222 -6.6599 24.7925
OVTOKO GDSC2; CTRP2 -6.492 -4.833 -6.5056 23.7782
OVSAHO CTRP2 -6.4474 -5.0951 -6.4516 23.448
IGROV-1 GDSC2; CTRP2; CTRP1 -6.2684 -5.0658 -6.2709 22.2454
ES2 CTRP2 -6.1282 -5.4407 -6.1283 21.2997
RMG-I GDSC2; CTRP2; CTRP1 -6.0557 -1.3344 -6.8834 25.426
TOV-112D GDSC2; CTRP2 -5.9809 -2.8493 -6.2845 21.3814
DOV13 GDSC2; CTRP2 -5.9229 -4.328 -5.9464 20.0054
SNU-119 CTRP2 -5.9211 -4.3464 -5.9432 19.9888
OVISE GDSC2; CTRP2 -5.8594 -4.9139 -5.8604 19.5047
OVCAR-5 GDSC2; CTRP2 -5.7738 -4.1067 -5.8093 19.0038
SK-OV-3 GDSC2; CTRP2; CTRP1 -5.7233 -3.7748 -5.7233 49.0711
JHOS-2 GDSC2; CTRP2 -5.6001 -1.3813 -6.3803 20.6181
COV434 CTRP2; CTRP1 -5.3977 -3.823 -5.4429 16.5279
EFO-21 GDSC2; CTRP2; CTRP1 -4.82 -1.8856 -4.8216 43.0394
OAW42 GDSC2; CTRP2; CTRP1 -4.8113 -2.3712 -5.1626 13.7591
EFO-27 GDSC2; CTRP2; CTRP1 -4.6295 -1.5274 -5.2982 13.7737
OVMANA CTRP1 -4.6289 -1.6484 -4.631 70.6527
HEY A8 CTRP2; CTRP1 -4.5265 -3.7341 -4.5265 43.6245
COV362 CTRP2; CTRP1 -3.2527 4.6576 -7.0046 17.3366
FU-OV-1 GDSC2; CTRP2 -3.1037 1.2718 -5.186 9.77
Kuramochi GDSC1; GDSC2; CTRP2 -2.8268 4.1411 -6.389 14.1319
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 -4.4976 -3.0999 -4.5995 10.723
SW872 GDSC1; GDSC2 -10.2093 -9.2796 -10.2094 45.8152
MFH-ino GDSC1; GDSC2 -10.0297 -7.8138 -10.0554 44.102
VA-ES-BJ GDSC1; GDSC2 -10.0097 -8.4078 -10.0134 43.8267
SW684 GDSC1; GDSC2 -9.885 -9.3046 -9.885 42.5604
Hs 633.T GDSC2 -7.7547 -6.3784 -7.7963 21.3947
G-402 GDSC2; CTRP2 -7.5264 -6.149 -7.5272 30.6531
MES-SA GDSC2; CTRP2 -7.3683 -6.2173 -7.3686 29.5939
STS-0421 GDSC2 -7.3636 -5.8032 -7.4797 17.8639
G-401 GDSC2; CTRP2; CTRP1 -7.0814 -5.1091 -7.0814 52.8878
HT-1080 GDSC2; CTRP2; CTRP1 -7.0353 -5.8917 -7.0357 27.3673
Rh18 CTRP2 -6.953 -5.631 -6.9545 26.8203
RKN GDSC2; CTRP2; CTRP1 -6.7627 -6.2083 -6.7627 27.3387
Hs 729.T CTRP2 -6.7289 -5.1535 -6.7362 25.3411
Rh41 GDSC2; CTRP2 -6.7228 -5.7997 -6.7229 25.2765
TE 617.T CTRP2 -6.72 -5.3152 -6.7235 25.2691
KYM-1 GDSC2; CTRP2 -6.6904 -5.4179 -6.6922 25.0057
A-204 GDSC2; CTRP2 -6.6345 -5.1935 -6.6392 24.6427
SK-UT-1 GDSC1; GDSC2; CTRP2 -6.6048 -4.6219 -6.6355 24.5905
RD GDSC2; CTRP2 -6.451 -4.6195 -6.4754 23.5404
SK-LMS-1 GDSC1; GDSC2; CTRP2 -6.22 -4.7962 -6.2282 21.9409
TTC-709 CTRP2 -6.1965 -5.4767 -6.1965 21.7046
EW-8 GDSC1; GDSC2 -5.9568 -2.5923 -7.4377 12.2733
Rh30 GDSC2 -5.6623 2.9411 -9.9517 24.3464
Tm87-16 CTRP2 -5.4661 -4.7016 -5.4666 16.833
BT-12 CTRP2 -5.2488 -4.8788 -5.2488 15.3811
GCT GDSC2; CTRP2 -5.1872 -3.2589 -5.3138 15.4081
SW982 GDSC2; CTRP2 -4.3038 -3.1357 -4.3803 9.3407
BT-16 CTRP2 -3.7637 -2.5102 -3.9854 6.2839
TE 441.T GDSC1; GDSC2; CTRP2 1.2532 14.4329 -8.4319 14.5644
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MPP 89 GDSC1; GDSC2 -8.5479 -4.2691 -9.2717 32.5965
NCI-H28 GDSC2; CTRP2; CTRP1 -7.0762 -6.0862 -7.0762 52.8653
IST-Mes1 GDSC1; GDSC2; CTRP2 -5.4225 -2.4698 -5.7917 17.898
ACC-MESO-1 CTRP2 -5.122 -3.8935 -5.1442 14.6449
MSTO-211H GDSC1; GDSC2; CTRP2; CTRP1 -5.0314 -3.241 -5.0314 43.957
NCI-H2452 GDSC2; CTRP2 -4.8989 -0.521 -6.0133 17.2993
NCI-H2052 GDSC2; CTRP2; CTRP1 -4.3596 -0.4291 -4.378 41.0668
JL-1 CTRP2 -3.0103 -0.3219 -4.3103 5.8984
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP2; CTRP1 -7.5363 -5.0011 -7.5363 54.8688
VCaP GDSC1; GDSC2; CTRP2 -7.3239 -4.4971 -7.4066 29.5744
22Rv1 GDSC2; CTRP2 -6.932 -4.3909 -7.0033 26.9166
PC-3 GDSC2 -6.2328 -4.1035 -6.9468 10.1372
LNCaP clone FGC GDSC1; GDSC2; CTRP2 -6.0166 -3.6591 -6.1325 20.9509
NCI-H660 GDSC2 -5.9947 -4.2569 -6.6477 7.455
DU145 GDSC2; CTRP2 -5.618 -0.9568 -6.5707 21.3839
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2; CTRP2 -7.235 -5.1933 -7.2531 28.762
YD-15 CTRP2 -6.0487 -5.3123 -6.0487 20.7677
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 -9.5376 -8.1252 -9.5406 39.0884
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GCIY GDSC1; GDSC2 -9.3479 -8.2412 -9.3485 37.1736
HSC-39 GDSC1; GDSC2 -8.4419 -7.3338 -8.4458 28.0982
HuG1-N CTRP2 -8.375 -6.8444 -8.3756 36.3277
RF-48 GDSC1; GDSC2 -8.307 -7.0329 -8.3186 26.7837
SNU-16 GDSC1; GDSC2; CTRP2 -8.1828 -7.5247 -8.1828 35.0399
TGBC11TKB GDSC2 -7.4543 -5.8599 -7.5651 18.7449
GSS CTRP2 -7.4094 -6.2579 -7.4096 29.8682
ECC10 GDSC2; CTRP2 -7.3345 -6.1606 -7.3348 29.3679
NCC-StC-K140 CTRP2 -7.2773 -3.8829 -7.4537 29.5805
RERF-GC-1B GDSC2 -7.2409 -4.5103 -7.7882 19.0575
SNU-620 CTRP2 -7.2246 -5.7758 -7.2266 28.6385
SNU-5 GDSC1; GDSC2; CTRP2 -7.1169 -5.4702 -7.1226 27.9309
SH-10-TC CTRP2; CTRP1 -7.1044 -5.5724 -7.1044 52.988
LMSU CTRP2 -7.0398 -5.5612 -7.0429 27.4062
MKN1 GDSC2; CTRP2 -6.9212 -4.4494 -6.985 30.8725
SNU-601 CTRP2 -6.7993 -4.0768 -6.9049 26.0849
SK-GT-2 GDSC2 -6.7903 -5.0699 -7.088 13.1395
Fu97 GDSC2; CTRP2; CTRP1 -6.6979 -4.8793 -6.6979 51.217
NCI-N87 GDSC1; GDSC2; CTRP2 -6.6806 -2.1731 -7.2555 26.9925
MKN28 GDSC2 -6.6387 -4.8697 -7.0077 12.045
NUGC-3 GDSC2; CTRP2 -6.631 -4.9585 -6.6731 21.0199
AGS GDSC2; CTRP2; CTRP1 -6.6249 -5.4077 -6.6263 24.6257
IM95 GDSC2; CTRP2 -6.4467 -5.2498 -6.4484 23.4352
MKN7 GDSC2; CTRP2; CTRP1 -6.3825 -3.494 -6.383 49.8432
23132/87 GDSC2; CTRP2 -6.3193 -5.6537 -6.3193 22.5776
TMK-1 GDSC2 -6.2983 -5.1307 -6.5426 7.9327
KATO III GDSC2 -6.2279 -3.9079 -7.0363 10.6736
SNU-216 CTRP2 -6.1267 -4.4574 -6.1494 21.3148
GSU CTRP2 -6.0615 -5.6991 -6.0615 20.8533
SNU-1 GDSC1; GDSC2; CTRP2 -5.9852 -4.2477 -6.0183 20.4548
SNU-668 CTRP2 -5.7961 -4.1681 -5.827 19.1828
ECC12 GDSC1; GDSC2; CTRP2 -5.7828 -5.1804 -5.7828 18.9896
SCH GDSC1; GDSC2 -5.4233 -2.4545 -7.0586 8.3295
NUGC-4 GDSC2; CTRP2; CTRP1 -5.3969 -2.0516 -5.4001 45.5547
OCUM-1 GDSC2; CTRP2 -5.3861 -3.3784 -5.5042 16.7439
HGC-27 GDSC2; CTRP2 -5.0315 -3.5527 -5.0894 14.1286
MKN74 CTRP2; CTRP1 -4.9681 -2.3763 -4.9686 43.6824
MKN45 GDSC2; CTRP2 -4.926 -3.7861 -4.9482 13.334
KE-39 CTRP2 -4.5556 -1.8834 -5.0738 12.6677
SNU-719 CTRP2 -4.1597 -0.0839 -5.4805 13.3134
Hs 746.T GDSC2; CTRP2 0.4048 2.2311 -3.5269 0.0981
SNG-M GDSC2; CTRP2; CTRP1 -7.4342 -6.4001 -7.4342 54.4246
SNU-685 CTRP2 -6.6137 -5.0611 -6.6215 24.5724
SNU-1077 CTRP2 -5.996 -4.0736 -6.0479 20.5912
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HTC-C3 GDSC2 -8.6012 -7.1948 -8.6137 29.7399
K5 GDSC1; GDSC2 -8.5528 -6.3515 -8.6571 29.7196
KMH-2 GDSC2 -8.128 -7.0599 -8.1339 24.9582
ASH-3 GDSC2 -7.836 -6.7909 -7.8454 22.0457
8505C GDSC2; CTRP2 -7.7788 -6.8216 -7.7788 32.3382
FTC-238 CTRP2 -7.2658 -6.136 -7.266 28.9082
8305C GDSC2; CTRP2 -6.5597 -4.9406 -6.5705 24.2212
IHH-4 GDSC2 -6.5313 -5.7077 -6.5957 9.2422
TT GDSC2; CTRP2 -6.077 -5.1349 -6.0776 20.9587
B-CPAP GDSC2; CTRP2 -6.0761 -5.4199 -6.0761 20.9507
CGTH-W-1 GDSC1; GDSC2; CTRP2 -5.9598 -4.9492 -5.9611 20.1774
CAL-62 GDSC2; CTRP2 -5.866 -4.7425 -5.8694 19.5572
BHT-101 GDSC2; CTRP2 -5.8437 -5.193 -5.8438 19.397
SW579 CTRP2 -5.7848 -4.6331 -5.7894 19.0183
WRO GDSC2 -5.3181 -0.6023 -7.8986 13.179
FTC-133 GDSC2; CTRP2 -5.0701 -0.8125 -6.0608 17.9375
ML-1 [Human leukemia] GDSC2; CTRP2 -3.5898 -0.2642 -4.8537 9.4061
TT2609-C02 GDSC2; CTRP2 -2.1409 4.8132 -6.1749 12.0126
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB771-HNC GDSC1; GDSC2 -10.8516 -7.8709 -10.9088 52.148
BB30-HNC GDSC1; GDSC2 -10.2483 -9.5128 -10.2483 46.2057
BB49-HNC GDSC1; GDSC2 -9.8888 -7.0944 -9.9761 42.9027
HO-1-u-1 GDSC2 -8.4915 -7.1989 -8.5007 28.6228
Ca9-22 GDSC2 -8.0899 -7.116 -8.0935 24.5644
JHU-011 GDSC2 -8.0843 -5.2487 -8.4247 26.2723
OSC-19 GDSC2 -8.0145 -6.7438 -8.0334 23.885
SAS GDSC2 -7.9939 -7.0492 -7.9975 23.6007
KOSC-2 GDSC2 -7.8891 -6.486 -7.9259 22.7184
OSC-20 GDSC2 -7.8382 -5.8484 -7.986 22.7903
PCI-04B GDSC2 -7.7814 -5.6037 -7.9877 22.5359
CAL-27 GDSC2; CTRP2 -7.6319 -5.7855 -7.6382 31.3771
SKN-3 GDSC2 -7.6256 -5.5296 -7.8389 21.0149
PE/CA-PJ49 CTRP2 -7.5602 -6.4666 -7.5603 30.8763
JHU-022 GDSC2 -7.5026 -5.4454 -7.7298 19.8603
NCI-H3118 GDSC2 -7.4936 -5.8636 -7.607 19.153
HO-1-N-1 GDSC2 -7.4894 -5.9255 -7.5886 19.0352
PCI-06A GDSC2 -7.3642 -4.1592 -8.0633 21.137
HSC-2 GDSC2; CTRP2; CTRP1 -7.2386 -5.6895 -7.2386 53.5727
SNU-1076 CTRP2 -7.1958 -5.7451 -7.1979 28.4465
KON GDSC2 -7.1942 -5.7111 -7.3179 16.2068
PCI-15A GDSC2 -6.9648 -5.6841 -7.0746 13.8328
BICR 78 GDSC2 -6.8434 -5.1835 -7.1023 13.4476
PCI-30 GDSC2 -6.7621 4.5665 -11.7084 33.2224
Detroit 562 GDSC2; CTRP2 -6.7291 -5.7603 -6.7292 25.3182
BICR 10 GDSC2 -6.7011 -5.5054 -6.8382 11.3407
SCC-9 GDSC2; CTRP2; CTRP1 -6.6597 -3.954 -6.7746 25.2463
JHU-029 GDSC2 -6.6589 -4.3559 -7.2511 13.5695
UPCI-SCC-090 GDSC2 -6.6393 -5.3591 -6.8195 10.9631
PE/CA-PJ15 GDSC2; CTRP2 -6.565 -4.4148 -6.6122 24.3805
SNU-1214 CTRP2 -6.5321 -4.3762 -6.5814 24.1674
BHY GDSC2; CTRP2 -6.3653 -5.3876 -6.3657 22.8864
DOK GDSC2 -6.1193 -2.0763 -7.8378 15.2323
SAT [Human HNSCC] GDSC2 -6.0502 3.2006 -10.4091 27.2209
HSC-3 GDSC2; CTRP2 -6.0379 -3.9536 -6.1079 20.9336
CAL-33 GDSC2; CTRP2 -6.0371 -4.9691 -6.0387 20.6461
SCC-4 GDSC2; CTRP2 -6.0013 -3.6585 -6.116 20.7949
HSC-4 GDSC2; CTRP2 -5.857 -5.073 -5.8601 14.9102
SCC-25 GDSC2; CTRP2 -5.7709 -3.9863 -5.8194 19.0744
YD-8 CTRP2 -5.7624 -2.9604 -6.0152 19.7392
YD-10B CTRP2 -5.646 -3.7913 -5.712 18.2996
PE/CA-PJ34 (clone C12) CTRP2 -5.6242 -3.1947 -5.8044 18.5558
SNU-899 CTRP2 -5.474 -4.1046 -5.4952 16.9956
SCC-15 GDSC1; GDSC2 -5.4261 1.265 -8.9185 19.0488
PE/CA-PJ41 (clone D2) CTRP2 -5.2651 -1.6562 -5.9163 17.9139
BICR 22 GDSC2; CTRP2 -5.2579 -4.0592 -5.2733 15.5307
BICR 56 CTRP2 -5.2092 -3.0748 -5.3815 15.7173
BICR 6 CTRP2 -5.194 -4.2636 -5.1981 15.0652
SNU-46 CTRP2 -4.8178 -3.3397 -4.896 12.8044
BICR 31 GDSC2; CTRP2 -4.7639 -0.0127 -6.1079 17.3231
BICR 18 CTRP2 -4.6591 -2.7096 -4.8845 12.2758
FaDu GDSC2; CTRP2 -4.5144 -0.8701 -5.4667 14.1383
BICR 16 CTRP2 -4.1288 -2.5276 -4.3705 8.7817
SNU-1066 CTRP2 -4.1029 -1.5704 -4.7356 10.157
SNU-1041 CTRP2 -2.5742 1.3338 -4.7827 7.0724
⏷ Show the Full List of 55 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RT-112 GDSC2; CTRP2 -7.4467 -6.0342 -7.4478 30.1208
U-BLC1 CTRP2 -7.4439 -6.7954 -7.4439 30.0272
SCaBER CTRP2 -7.423 -6.3526 -7.4231 29.959
SW1710 GDSC2; CTRP2 -7.3387 -5.8457 -7.3408 29.4021
647V GDSC2; CTRP2 -7.2828 -5.7898 -7.2851 29.0288
UM-UC-1 CTRP2 -7.1184 -5.4094 -7.1257 27.9461
5637 GDSC2; CTRP2; CTRP1 -6.9267 -5.0552 -6.9267 52.2136
JMSU-1 CTRP2 -6.9053 -6.0367 -6.9054 26.4967
HT-1197 GDSC2; CTRP2 -6.8891 -4.9253 -6.9105 26.4599
BC-3C CTRP2 -6.8834 -5.3912 -6.8875 26.3638
TCCSUP GDSC2; CTRP2 -6.8795 -5.8556 -6.8797 26.3248
CAL-29 GDSC2; CTRP2 -6.8139 -5.2278 -6.8206 25.9075
BFTC-905 GDSC2; CTRP2 -6.8005 -5.6019 -6.8015 25.7988
KMBC-2 CTRP2; CTRP1 -6.6289 -5.3939 -6.6289 50.8375
J82 GDSC2; CTRP2 -6.621 -4.8563 -6.6373 24.6496
RT-4 GDSC2; CTRP2; CTRP1 -6.5485 -5.4882 -6.5485 52.8267
SW780 GDSC2 -6.4343 -3.6717 -7.347 13.3167
UM-UC-3 GDSC2; CTRP2; CTRP1 -6.2457 -5.0884 -6.2457 51.4485
T24 GDSC2; CTRP2 -6.0346 -2.9281 -6.3211 21.6773
VM-CUB-1 CTRP2 -6.005 -4.5076 -6.0201 20.5263
253J-BV CTRP2 -5.9792 -3.6011 -6.1029 20.7283
639V GDSC2; CTRP2 -5.8681 -5.3066 -5.8681 19.5601
253J CTRP2 -5.8357 -4.5804 -5.8429 19.3672
HT-1376 GDSC2; CTRP2; CTRP1 -5.7618 -2.4707 -5.764 49.2473
KU-19-19 GDSC2; CTRP2 -4.0268 -0.5738 -5.119 11.5183
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DSH1 GDSC1; GDSC2 -11.3433 -9.9256 -11.3435 57.1863
NT2-D1 GDSC1; GDSC2 -11.1884 -10.254 -11.1884 55.6397
LB831-BLC GDSC1; GDSC2 -10.4763 -8.9067 -10.4779 48.4968
NEC8 GDSC1; GDSC2 -8.6644 -7.3712 -8.6713 30.346
SW954 GDSC1; GDSC2 -8.5802 -6.4673 -8.667 29.9054
DoTc2 4510 GDSC2 -8.5083 -7.1665 -8.5195 28.8014
KGN GDSC1; GDSC2 -8.0764 -5.911 -8.2307 25.2109
Ca Ski GDSC2 -7.9978 -5.8991 -8.1478 24.4007
PWR-1E GDSC2 -7.9946 -6.537 -8.0319 23.7797
NCC-IT GDSC1; GDSC2 -7.815 -5.7522 -7.9846 22.6743
C-4-I GDSC2 -7.6538 -6.69 -7.6627 20.2146
SiSo GDSC2 -7.4914 -5.7945 -7.621 19.2177
JHOS-3 GDSC2 -7.4155 -5.9738 -7.4982 18.2067
OVCA420 GDSC2 -7.3979 -5.4334 -7.6195 18.7815
OV17R GDSC2 -7.3924 -5.3668 -7.6343 18.8388
OVCA433 GDSC2 -7.3243 -5.5618 -7.5008 17.7976
HEC-1 GDSC2 -7.251 -5.5819 -7.4151 16.9953
PA-1 GDSC2 -7.2487 -5.3806 -7.4736 17.3072
SKN GDSC2 -7.2431 -5.5122 -7.4269 17.0242
CAL-39 GDSC2 -7.1663 -5.6519 -7.3031 15.9984
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 -7.1446 -4.2626 -7.7911 18.6789
UWB1.289 GDSC2 -7.0317 -4.4686 -7.5863 17.0299
ACC-OV7 GDSC2 -7.0254 8.7726 -14.0334 38.1764
C-33 A GDSC2 -7.0038 -5.5143 -7.1653 14.5054
SW962 GDSC1; GDSC2 -6.9077 -4.9032 -7.2779 14.7272
JEG-3 GDSC2 -6.6949 -4.7915 -7.099 12.8094
PEO1 GDSC2 -6.6275 -3.6227 -7.5576 15.2972
JAR GDSC1; GDSC2 -6.5997 -4.2185 -7.2534 13.3567
BPH-1 GDSC2 -6.5552 5.3375 -11.9113 33.0688
SW756 GDSC2 -6.4685 -4.2872 -7.0907 11.8775
ME-180 GDSC2 -6.0933 -0.1476 -8.775 20.3766
OVMIU GDSC2 -6.0901 3.107 -10.3964 27.3
HEY GDSC2 -5.9485 5.1725 -11.3079 29.7346
SKG-IIIa GDSC2 -5.9003 -3.2915 -7.04 9.6111
SiHa GDSC2 -5.8314 -3.7423 -6.7551 7.6006
TC-YIK GDSC1; GDSC2 -5.5151 -2.8933 -6.9133 7.6683
HT-3 GDSC2 -5.3635 0.8096 -8.64 17.4447
HeLa GDSC2; CTRP2 -4.9909 -3.9705 -5.0021 13.7308
MS751 GDSC2 -1.2734 10.7329 -10.539 16.5117
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bortezomib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Carfilzomib DM48K0X Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Carfilzomib. Multiple myeloma [2A83] [16]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Thalidomide. Multiple myeloma [2A83] [16]
Elotuzumab DMEYHG9 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Elotuzumab. Multiple myeloma [2A83] [16]
Coadministration of a Drug Treating the Disease Different from Bortezomib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [17]
Metreleptin DM1NOEK Minor Increased metabolism of Bortezomib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [18]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Thioguanine. Acute myeloid leukaemia [2A60] [19]
Ivosidenib DM8S6T7 Minor Increased metabolism of Bortezomib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [18]
Arn-509 DMT81LZ Major Increased metabolism of Bortezomib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [18]
Mitotane DMU1GX0 Major Increased metabolism of Bortezomib caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [18]
Metronidazole DMTIVEN Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Metronidazole. Amoebiasis [1A36] [16]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Butalbital DM9J04X Minor Increased metabolism of Bortezomib caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [18]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Bortezomib caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [18]
Clobazam - Lundbeck DMW1OQ0 Minor Decreased metabolism of Bortezomib caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [21]
Cilostazol DMZMSCT Moderate Decreased metabolism of Bortezomib caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [22]
Voriconazole DMAOL2S Moderate Decreased metabolism of Bortezomib caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [23]
Posaconazole DMUL5EW Moderate Decreased metabolism of Bortezomib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [23]
Zafirlukast DMHNQOG Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Zafirlukast. Asthma [CA23] [16]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Bortezomib and Roflumilast. Asthma [CA23] [18]
Oritavancin DM28D05 Minor Increased metabolism of Bortezomib caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [18]
Tindamax DM3OWT4 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Tindamax. Bacterial infection [1A00-1C4Z] [16]
Erythromycin DM4K7GQ Moderate Decreased metabolism of Bortezomib caused by Erythromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [23]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Bortezomib caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [23]
Chloramphenicol DMFXEWT Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Chloramphenicol. Bacterial infection [1A00-1C4Z] [16]
Linezolid DMGFPU2 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Linezolid. Bacterial infection [1A00-1C4Z] [16]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Bortezomib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [23]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Bortezomib caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [23]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Bortezomib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [24]
Eribulin DM1DX4Q Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Eribulin. Breast cancer [2C60-2C6Y] [16]
Ixabepilone DM2OZ3G Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Ixabepilone. Breast cancer [2C60-2C6Y] [16]
Tucatinib DMBESUA Moderate Decreased metabolism of Bortezomib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Alpelisib DMEXMYK Moderate Increased metabolism of Bortezomib caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Cabazitaxel DMPAZHC Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Cabazitaxel. Breast cancer [2C60-2C6Y] [16]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [16]
Atorvastatin DMF28YC Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [16]
Secobarbital DM14RF5 Minor Increased metabolism of Bortezomib caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [18]
Phenylbutazone DMAYL0T Minor Increased metabolism of Bortezomib caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [18]
Oxaliplatin DMQNWRD Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Oxaliplatin. Colorectal cancer [2B91] [16]
Mifepristone DMGZQEF Moderate Decreased metabolism of Bortezomib caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [17]
Lumacaftor DMCLWDJ Major Increased metabolism of Bortezomib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [23]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Bortezomib caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [23]
Griseofulvin DMK54YG Minor Increased metabolism of Bortezomib caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [18]
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and PMID28454500-Compound-96. Discovery agent [N.A.] [16]
Citalopram derivative 1 DMITX1G Minor Decreased metabolism of Bortezomib caused by Citalopram derivative 1 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [21]
Diazepam DM08E9O Minor Decreased metabolism of Bortezomib caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Primidone DM0WX6I Major Increased metabolism of Bortezomib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Felbamate DM1V5ZS Minor Increased metabolism of Bortezomib caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Oxcarbazepine DM5PU6O Minor Increased metabolism of Bortezomib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Mephenytoin DM5UGDK Minor Decreased metabolism of Bortezomib caused by Mephenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Valproate DMCFE9I Minor Decreased metabolism of Bortezomib caused by Valproate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cenobamate DM8KLU9 Minor Increased metabolism of Bortezomib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Stiripentol DMMSDOY Moderate Decreased metabolism of Bortezomib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Fosphenytoin DMOX3LB Major Increased metabolism of Bortezomib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Rufinamide DMWE60C Minor Increased metabolism of Bortezomib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Phenobarbital DMXZOCG Major Increased metabolism of Bortezomib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Carbamazepine DMZOLBI Major Increased metabolism of Bortezomib caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Eslicarbazepine DMZREFQ Minor Increased metabolism of Bortezomib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Tazemetostat DMWP1BH Minor Increased metabolism of Bortezomib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [18]
Itraconazole DMCR1MV Moderate Decreased metabolism of Bortezomib caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
Terbinafine DMI6HUW Minor Decreased metabolism of Bortezomib caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [21]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Bortezomib caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Bortezomib caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
Omeprazole DM471KJ Minor Decreased metabolism of Bortezomib caused by Omeprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [21]
Pantoprazole DMSVOCZ Minor Decreased metabolism of Bortezomib caused by Pantoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [21]
Colchicine DM2POTE Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Colchicine. Gout [FA25] [16]
Sulfinpyrazone DMEV954 Minor Increased metabolism of Bortezomib caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [18]
Boceprevir DMBSHMF Moderate Decreased metabolism of Bortezomib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [23]
Telaprevir DMMRV29 Moderate Decreased metabolism of Bortezomib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [23]
Telbivudine DMSWUGE Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Telbivudine. Hepatitis virus infection [1E50-1E51] [16]
Isoniazid DM5JVS3 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [16]
Rifampin DMA8J1G Major Increased metabolism of Bortezomib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [23]
Rifapentine DMCHV4I Major Increased metabolism of Bortezomib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [18]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [28]
Indinavir DM0T3YH Moderate Decreased metabolism of Bortezomib caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Delavirdine DM3NF5G Moderate Decreased metabolism of Bortezomib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Bortezomib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Stavudine DM6DEK9 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [16]
Nevirapine DM6HX9B Minor Increased metabolism of Bortezomib caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Bortezomib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Efavirenz DMC0GSJ Minor Increased metabolism of Bortezomib caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Saquinavir DMG814N Moderate Decreased metabolism of Bortezomib caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Etravirine DMGV8QU Minor Increased metabolism of Bortezomib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [16]
Didanosine DMI2QPE Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Didanosine. Human immunodeficiency virus disease [1C60-1C62] [16]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Bortezomib caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Atazanavir DMSYRBX Moderate Decreased metabolism of Bortezomib caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Ritonavir DMU764S Moderate Decreased metabolism of Bortezomib caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Fluvastatin DM4MDJY Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Fluvastatin. Hyper-lipoproteinaemia [5C80] [16]
Lovastatin DM9OZWQ Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Lovastatin. Hyper-lipoproteinaemia [5C80] [16]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Bortezomib and Mipomersen. Hyper-lipoproteinaemia [5C80] [29]
Rosuvastatin DMMIQ7G Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [16]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Bortezomib and BMS-201038. Hyper-lipoproteinaemia [5C80] [30]
Hydralazine DMU8JGH Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Hydralazine. Hypertension [BA00-BA04] [16]
Conivaptan DM1V329 Moderate Decreased metabolism of Bortezomib caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [31]
Pirfenidone DM6VZFQ Minor Decreased metabolism of Bortezomib caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [21]
Lesinurad DMUR64T Minor Increased metabolism of Bortezomib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [18]
Auranofin DMWE2N4 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Auranofin. Inflammatory arthropathy [FA2Z] [16]
Amobarbital DM0GQ8N Minor Increased metabolism of Bortezomib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Butabarbital DMC5AST Minor Increased metabolism of Bortezomib caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Pentobarbital DMFNH7L Minor Increased metabolism of Bortezomib caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Quazepam DMY4D87 Minor Decreased metabolism of Bortezomib caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [21]
Nelarabine DMB6VEG Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Nelarabine. Leukaemia [2A60-2B33] [16]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Bortezomib caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [18]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Bortezomib and Denosumab. Low bone mass disorder [FB83] [32]
Brigatinib DM7W94S Minor Increased metabolism of Bortezomib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Ceritinib DMB920Z Moderate Decreased metabolism of Bortezomib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [23]
PF-06463922 DMKM7EW Moderate Increased metabolism of Bortezomib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [17]
Osimertinib DMRJLAT Minor Increased metabolism of Bortezomib caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Selpercatinib DMZR15V Moderate Decreased metabolism of Bortezomib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
Chloroquine DMSI5CB Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Chloroquine. Malaria [1F40-1F45] [16]
Hydroxychloroquine DMSIVND Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Hydroxychloroquine. Malaria [1F40-1F45] [16]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [34]
Cladribine DM3JDRP Major Additive myelosuppressive effects by the combination of Bortezomib and Cladribine. Mature B-cell leukaemia [2A82] [18]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Idelalisib. Mature B-cell leukaemia [2A82] [35]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Clofarabine. Mature B-cell lymphoma [2A85] [36]
Vincristine DMINOX3 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Vincristine. Mature B-cell lymphoma [2A85] [16]
Teniposide DMLW57T Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Teniposide. Mature B-cell lymphoma [2A85] [16]
Ponatinib DMYGJQO Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Ponatinib. Mature B-cell lymphoma [2A85] [16]
Vemurafenib DM62UG5 Minor Increased metabolism of Bortezomib caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [18]
Ipilimumab DMJTIYK Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Ipilimumab. Melanoma [2C30] [16]
Dabrafenib DMX6OE3 Minor Increased metabolism of Bortezomib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [18]
Propranolol DM79NTF Minor Decreased metabolism of Bortezomib caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [21]
Exjade DMHPRWG Minor Increased metabolism of Bortezomib caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [18]
Flibanserin DM70DTN Minor Decreased metabolism of Bortezomib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [21]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Bortezomib and Tecfidera. Multiple sclerosis [8A40] [37]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Bortezomib and Siponimod. Multiple sclerosis [8A40] [17]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Bortezomib and Fingolimod. Multiple sclerosis [8A40] [38]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Bortezomib and Ocrelizumab. Multiple sclerosis [8A40] [39]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Bortezomib and Ozanimod. Multiple sclerosis [8A40] [18]
Carisoprodol DMWR1JC Minor Decreased metabolism of Bortezomib caused by Carisoprodol mediated inhibition of CYP450 enzyme. Musculoskeletal disorder [FA00-FC0Z] [21]
Rifabutin DM1YBHK Major Increased metabolism of Bortezomib caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [18]
Bexarotene DMOBIKY Minor Increased metabolism of Bortezomib caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [18]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Bortezomib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [18]
Nilotinib DM7HXWT Moderate Decreased metabolism of Bortezomib caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [40]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Bortezomib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [41]
Modafinil DMYILBE Minor Increased metabolism of Bortezomib caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [18]
Carboplatin DMG281S Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Carboplatin. Ovarian cancer [2C73] [16]
Levodopa DMN3E57 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Levodopa. Parkinsonism [8A00] [16]
Abametapir DM2RX0I Moderate Decreased metabolism of Bortezomib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [42]
Esomeprazole DM7BN0X Minor Decreased metabolism of Bortezomib caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [21]
Dapsone DM4LT8A Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Dapsone. Pneumonia [CA40] [16]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Bortezomib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [23]
Enzalutamide DMGL19D Major Increased metabolism of Bortezomib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [18]
Bosentan DMIOGBU Minor Increased metabolism of Bortezomib caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [18]
Tocilizumab DM7J6OR Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Tocilizumab. Rheumatoid arthritis [FA20] [16]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Bortezomib and Canakinumab. Rheumatoid arthritis [FA20] [43]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Bortezomib and Rilonacept. Rheumatoid arthritis [FA20] [43]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Bortezomib and Golimumab. Rheumatoid arthritis [FA20] [44]
Dexamethasone DMMWZET Minor Increased metabolism of Bortezomib caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [18]
Nafcillin DMN9RPO Minor Increased metabolism of Bortezomib caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [18]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Bortezomib and Leflunomide. Rheumatoid arthritis [FA20] [45]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Bortezomib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [46]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Bortezomib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [18]
Vinblastine DM5TVS3 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Vinblastine. Solid tumour/cancer [2A00-2F9Z] [16]
Docetaxel DMDI269 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [16]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [18]
Armodafinil DMGB035 Minor Increased metabolism of Bortezomib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Etoposide DMNH3PG Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Etoposide. Solid tumour/cancer [2A00-2F9Z] [16]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [17]
Cisplatin DMRHGI9 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [16]
Taxol DMUOT9V Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Taxol. Solid tumour/cancer [2A00-2F9Z] [16]
Vinorelbine DMVXFYE Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [16]
Disulfiram DMCL2OK Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Disulfiram. Substance abuse [6C40] [16]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Bortezomib and Naltrexone. Substance abuse [6C40] [47]
Warfarin DMJYCVW Minor Decreased metabolism of Bortezomib caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [21]
Anagrelide DMSQ8MD Moderate Decreased metabolism of Bortezomib caused by Anagrelide mediated inhibition of CYP450 enzyme. Thrombocytosis [3B63] [17]
Clopidogrel DMOL54H Moderate Decreased metabolism of Bortezomib caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [48]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Bortezomib and Azathioprine. Transplant rejection [NE84] [17]
Ethambutol DMR87LC Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Ethambutol. Tuberculosis [1B10-1B12] [16]
Nitrofurantoin DM7PQIK Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Nitrofurantoin. Urinary tract infection [GC08] [16]
Elagolix DMB2C0E Minor Increased metabolism of Bortezomib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [18]
Secnidazole DMJ18YL Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Secnidazole. Vaginal discharge [MF3A] [16]
Amiodarone DMUTEX3 Moderate Increased risk of peripheral neuropathy by the combination of Bortezomib and Amiodarone. Ventricular tachyarrhythmia [BC71] [16]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Bortezomib and Valganciclovir. Virus infection [1A24-1D9Z] [17]
⏷ Show the Full List of 171 DDI Information of This Drug

References

1 Bortezomib FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
4 FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use
5 BDDCS applied to over 900 drugs
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.
11 Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
14 Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7.
15 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
16 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
17 Cerner Multum, Inc. "Australian Product Information.".
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Product Information. Velcade (bortezomib). Millennium Pharmaceuticals Inc, Cambridge, MA.
22 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
23 Pekol T, Daniels JS, Labutti J, et al "Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites." Drug Metab Dispos 33 (2005): 771-7. [PMID: 15764713]
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
26 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
27 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
28 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
29 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
30 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
31 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
32 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
33 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
34 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
35 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
36 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
37 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
38 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
39 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
40 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
42 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
43 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
44 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
45 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
46 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
47 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
48 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]